<PAGE> 1
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM 10-K
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM ____________ TO ____________.
COMMISSION FILE NUMBER 0-14732
ADVANCED MAGNETICS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 04-2742593
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
61 MOONEY STREET 02138
CAMBRIDGE, MASSACHUSETTS (ZIP CODE)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (617) 497-2070
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
COMMON STOCK, PAR VALUE $.01 PER SHARE, AMERICAN STOCK EXCHANGE
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: NONE
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. YES [X] NO [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]
As of December 7, 1999, there were 6,752,027 shares of the registrant's
Common Stock, $.01 par value per share, outstanding. The aggregate market value
of the registrant's voting stock held by nonaffiliates as of December 7, 1999
was approximately $24,895,020.
DOCUMENTS INCORPORATED BY REFERENCE
PORTIONS OF THE REGISTRANT'S PROXY STATEMENT FOR ITS 1999 ANNUAL MEETING OF
STOCKHOLDERS, SCHEDULED TO BE HELD ON FEBRUARY 1, 2000, ARE INCORPORATED BY
REFERENCE IN PART III HEREOF.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
PART I
ITEM 1. BUSINESS:
COMPANY OVERVIEW
Advanced Magnetics, Inc., a Delaware corporation ("Advanced Magnetics" or
the "Company"), develops, manufactures and markets organ-specific contrast
agents to improve the diagnostic capabilities of soft tissue magnetic resonance
imaging ("MRI") scans. The Company's liver contrast agent, Feridex I.V.(R), is
approved and marketed in Europe, Japan, the United States, Argentina, South
Korea, China and Israel. The Company's oral contrast agent, GastroMARK(R), used
for delineating the bowel in MRI procedures, is approved and marketed in Europe
and the United States. The Company anticipates submitting a New Drug Application
("NDA") for Combidex(R), the Company's contrast agent for the diagnosis of lymph
node and liver disease, to the U.S. Food and Drug Administration ("FDA") before
the end of calendar 1999. Code 7228, the Company's lead MRI contrast agent in
the development pipeline, has completed Phase I clinical studies in the United
States. The product is being evaluated for both cardiology and oncology MRI
applications.
MRI is a diagnostic imaging technique that is used to visualize internal
abnormalities and changes in structure. Contrast agents increase the usefulness
of MRI by allowing physicians to differentiate structures and organs with
greater diagnostic confidence. Currently, the primary use of MRI is for studies
of the central nervous system, abdominal structures and joints such as the knee
and shoulder. The Company believes that the development of effective contrast
agents would allow MRI to be used for a wider range of applications and should
increase the use of MRI as a diagnostic imaging technique, in turn generating
additional demand for MRI contrast agents.
The liver and the lymphatic system are among the principal sites where
metastases of many common cancers (including colon, prostate and breast cancer)
are discovered. The Company believes that MRI exams of the liver produced with
contrast agents provide more diagnostic information and permit the
identification of smaller abnormalities than images produced by MRI studies
without contrast agents or images produced by contrast enhanced computed
tomography ("CECT"). Additionally, the Company believes that MRI exams of lymph
nodes using a contrast agent provide increased confidence in the diagnosis of
metastatic disease. As a result, MRI contrast agents frequently allow for more
accurate diagnosis and monitoring of treatment results and may be a
cost-effective way to assess medical treatments and to improve patient outcomes.
CECT is currently the primary imaging technique used to confirm a
preliminary or suspected diagnosis of liver cancer. Feridex I.V. is the first
organ-specific MRI contrast agent designed specifically for the liver and is
marketed in the United States, Europe, Japan, Argentina, South Korea, China and
Israel. With respect to the lymphatic system, there are no contrast agents
currently available. An MRI contrast agent that localizes to and causes contrast
enhancement of the lymph nodes, such as Combidex, could allow for more accurate
disease diagnosis and monitoring of treatment results. The Company also believes
that GastroMARK, because it enhances the contrast between the bowel and other
abdominal structures, may increase the use of MRI for diagnosing abdominal
disease.
To facilitate the marketing and distribution of its contrast agents, the
Company has entered into strategic relationships with certain established
pharmaceutical companies. These marketing and distribution partners, both in the
United States and abroad, include: (i) Guerbet S.A. ("Guerbet"), a leading
European producer of contrast agents, in Western Europe and Brazil; (ii) Eiken
Chemical Co., Ltd., ("Eiken"), one of Japan's leading medical diagnostics
manufacturers, in Japan; (iii) Berlex Laboratories, Inc. ("Berlex"), the leading
U.S. marketer of MRI contrast agents, in the United States; and (iv)
Mallinckrodt Inc. ("Mallinckrodt"), a leading manufacturer of contrast agents,
in the United States, Canada and Mexico.
The Company was incorporated in Delaware in November 1981. The Company's
principal offices are located at 61 Mooney Street, Cambridge, Massachusetts
02138, and its telephone number is (617) 497-2070.
1
<PAGE> 3
MRI CONTRAST AGENTS
Diagnostic Imaging. Diagnostic imaging is generally a non-invasive method
to visualize internal structures, abnormalities or anatomical changes in order
to diagnose disease and injury. Today, the most widely accepted imaging
techniques include x-rays, ultrasound, nuclear medicine, Computed Tomography
("CT") and MRI. Since the introduction of x-rays, doctors have sought
increasingly accurate and detailed non-invasive visualization of soft tissue for
diagnostic purposes. Diagnostic imaging is frequently used to determine whether
a cancer has metastasized or recurred and where it is located, as well as to
assist physicians in determining whether a treated cancer has shrunk. In
addition, diagnostic imaging is used in the diagnosis of disease affecting the
cardiovascular and central nervous systems as well as diagnosis of broken bones
and injuries in certain joints, such as the knee and shoulder. The choice of
diagnostic imaging technique to be used in any particular circumstance depends
upon a variety of factors, including the particular disease or condition to be
studied, image quality, availability of imaging machines, availability of
contrast agents, cost and managed health care policies. There is no imaging
technique that is considered superior to all others for most or all
applications.
Magnetic Resonance Imaging. Introduced in the 1980's, MRI is the diagnostic
imaging technique of choice for the central nervous system and is widely used
for the imaging of ligaments and tendons. MRI, which represents the first major
advance in imaging since the advent of CT scanning, provides high-quality
spatial resolution and does not use radiation. In MRI procedures, the patient is
placed within the core of a large magnet where radio frequency signals are
transmitted into the patient's body. The interaction of the radio frequency
signal with the patient's body produces signals that are processed by a computer
to create cross-sectional images. MRI contrast agents currently marketed in the
United States are used primarily in imaging the central nervous system.
Contrast Agents. Contrast agents play a significant role in improving the
quality of diagnostic images by increasing contrast between different internal
structures or types of tissues in various disease states and medical conditions
of interest. Consequently, contrast agents, which are administered intravenously
or orally, are widely used when available. The availability of effective
contrast agents often determines the choice of imaging technique for a
particular procedure. Currently available imaging techniques can be of limited
usefulness in visualizing certain soft-tissue structures. For example,
diagnostic imaging of lymph nodes, a common site of metastasis for some
frequently occurring cancers such as breast cancer and prostate cancer, is
currently limited because, the Company believes, there are no effective contrast
agents for differentiating diseased tissue from normal nodes.
TECHNOLOGY
Advanced Magnetics' core imaging agent technology is based on the
characteristic properties of extremely small, polysaccharide-coated
superparamagnetic iron oxide particles. The Company's core competencies are the
ability to design such particles for particular applications and manufacture the
particles in controlled sizes. The superparamagnetic particles range in size
from approximately one-thousandth to one-twentieth the size of a normal red
blood cell. When placed in a magnetic field, superparamagnetic iron oxide
particles become strongly magnetic, but lose their magnetism once the field is
removed. Once inside the targeted organ or area of study, the powerful magnetic
properties of the Company's iron oxide particles result in images that show
greater soft tissue contrast and thus increase the information available to the
reviewing radiologist. The Company's technology and expertise enable it to
synthesize, sterilize and stabilize superparamagnetic particles in a manner
necessary for their use in pharmaceutical products such as MRI contrast agents
to aid in the diagnosis of cancer and other diseases. The Company's rights to
its contrast agent technology are derived from and protected by license
agreements, patents, patent applications and trade secrets. See "Patents and
Trade Secrets."
2
<PAGE> 4
PRODUCTS
The following table summarizes applications, marketing partners and current
U.S. and foreign status for each of the Company's products.
ADVANCED MAGNETICS' PRODUCTS
<TABLE>
<CAPTION>
PRODUCT APPLICATIONS MARKETING PARTNERS U.S. STATUS FOREIGN STATUS
- ------- ------------ ------------------ ----------- --------------
<S> <C> <C> <C> <C>
Combidex Diagnosis of Guerbet (western NDA anticipated Dossier filed
lymph node Europe and before the end of December 1999 for
disease and Brazil). calendar 1999. lymph node
lesions of the indication.
liver and spleen.
Feridex I.V. Diagnosis of Berlex (United Approved and Approved and
liver lesions. States), Eiken marketed. marketed in Japan
(Japan), Guerbet and in most EU
(western Europe countries.
and Brazil).
GastroMARK Marking of the Guerbet (western Approved and Approved and
bowel in Europe and marketed. marketed in many
abdominal Brazil), EU countries
imaging. Mallinckrodt including France.
(United States,
Canada and
Mexico).
Code 7228 Magnetic Guerbet (western Phase I clinical
Resonance Europe and trial completed.
Angiography, Brazil).
primary and
secondary tumor
imaging, lymph
node imaging.
</TABLE>
"Phase I clinical trials" refers to the first phase of human pharmaceutical
clinical trials in which testing for the safety and tolerance of the product is
conducted on a small group of normal subjects. "Phase II clinical trials" and
"Phase III clinical trials" are the second and third phases of human clinical
trials, where preliminary dosing and efficacy studies are conducted and where
additional testing for efficacy and safety is conducted on an expanded patient
group. "NDA" is a New Drug Application that is filed with the U.S. Food and Drug
Administration ("FDA") when seeking marketing approval for a product in the
United States. "Dossier" is the EU equivalent of an NDA and is filed with the
Committee for Proprietary Medicinal Products, the EU equivalent of the FDA. For
a further description of the substantial regulatory requirements subsequent to
the completion of preclinical testing, see "Government Regulation and
Reimbursement."
Combidex. The Company believes that Combidex will be useful in the
diagnostic imaging of lymph nodes and well-perfused abdominal organs (liver and
spleen). Lymph nodes are frequently the site for metastases of different types
of cancer, particularly breast cancer and prostate cancer. Effective imaging of
lymph nodes could play a major role in determining appropriate patient
management. There are currently no available non-invasive methods for
distinguishing between lymph nodes enlarged by the infiltration of cancerous
cells as opposed to inflammation. Since CT, the only imaging modality currently
used for imaging lymph nodes, cannot distinguish between inflamed nodes and
cancerous nodes, the current practice is to assume that enlarged nodes are
cancerous and to perform a biopsy to establish their true status. Nodes less
than ten millimeters in size are assumed to be normal. The Company believes that
Combidex will enable doctors using MRI to have improved diagnostic confidence in
differentiating between normal and diseased lymph nodes, irrespective of node
size, because Combidex only accumulates in normal lymph node tissue and can
therefore facilitate differentiation between tumorous nodes and inflamed nodes.
The Company also believes that Combidex can be used to identify tumors in the
liver and spleen because tumors have different
3
<PAGE> 5
vascularity in comparison to surrounding tissue and can therefore be
differentiated by how the agent is absorbed.
The Company has granted exclusive rights to market and sell Combidex in
western Europe and Brazil to Guerbet. See "Licensing and Marketing
Arrangements."
Feridex I.V. The liver is a principal site for metastasis of primary
cancers originating in other parts of the body, particularly colon cancer, a
common cancer in the United States. Identification of metastatic tumors in the
liver has a significant impact on physicians' treatment plans for cancer because
proper staging of disease affects treatment plans. Diagnosis of metastases at an
early stage can be difficult because small tumors are frequently not accompanied
by detectable physical symptoms. The Company believes that contrast-enhanced MRI
exams using Feridex I.V. allow for the ability to image liver tumors that may
not be visible with CT scanning or ultrasound, the most widely used techniques
for liver imaging, and that a substantial number of liver scans may now be done
using MRI instead of, or in addition to, CT scanning and ultrasound.
Marketing of Feridex I.V. began in October 1996 by Berlex in the United
States. Berlex is the Company's exclusive marketing partner for Feridex I.V. in
the United States. Feridex I.V. was approved in August 1994 by the European
Union's (the "EU") Committee for Proprietary Medicinal Products and most of the
member states of the EU have since issued local approvals to market the product.
Guerbet began marketing the product in Europe in late 1994. Eiken received
approval for marketing the product in Japan in July 1997 and received pricing
approval in September 1997. Feridex I.V. was launched in Japan in September 1997
through Eiken's affiliate Tanabe Seiyaku, Ltd. See "Licensing and Marketing
Arrangements."
GastroMARK. MRI imaging of organs and tissues in the abdomen without
contrast agents is difficult because these organs and tissues cannot be easily
distinguished from the loops of the bowel. GastroMARK, the Company's oral
contrast agent for marking of the bowel, when ingested, flows through and
darkens the bowel. By more clearly identifying the intestinal loops, GastroMARK
improves visualization of adjacent abdominal tissues, such as the pancreas.
In April 1997, the Company's marketing partner, Mallinckrodt, launched
GastroMARK in the United States. The Company has licensed the marketing rights
to GastroMARK on an exclusive basis to Guerbet in western Europe and Brazil.
During fiscal 1993, Guerbet received marketing approval for the product in
several European countries including France, and marketing of the product in
Europe began. See "Licensing and Marketing Arrangements."
Code 7228. Code 7228 is a blood pool agent, an agent that stays in the
blood stream for an extended period of time, that may be useful as a contrast
agent for Magnetic Resonance Angiography ("MRA") as well as cardiac perfusion.
In addition, Code 7228 may be useful for the detection of metastatic and primary
tumors, including breast cancer, and may also improve tumor border delineation.
A Phase I clinical study of Code 7228 has been completed and the data is
currently being evaluated in order to plan appropriate Phase II studies.
The Company has granted exclusive rights to market and sell Code 7228 in
western Europe and Brazil to Guerbet. See "Licensing and Marketing
Arrangements."
LICENSING AND MARKETING ARRANGEMENTS
BERLEX. In February 1995, the Company entered into a license and marketing
agreement and a supply agreement with Berlex, granting Berlex exclusive
marketing rights to Feridex I.V. in the United States. Under the terms of the
agreements, Berlex paid a $5,000,000 license fee upon execution of the
agreements and paid an additional $5,000,000 license fee in October 1996 upon
the Company's delivery of FDA-approved product to Berlex. In addition, Berlex
pays the Company for manufacturing the agent and royalties on sales of the
agent. Under the terms of the licensing and marketing agreement Berlex pays for
60% of ongoing development expenses associated with Feridex I.V. These
agreements expire in 2010 but can be terminated earlier upon the occurrence of
certain specified events. Under the terms of the agreement, the Company has the
right to terminate the exclusivity of the marketing rights based on inadequate
sales performance by Berlex, but has not exercised that right at this time.
4
<PAGE> 6
EIKEN. In 1988, the Company entered into a manufacturing and distribution
agreement with Eiken, granting Eiken the exclusive right to manufacture and
distribute Feridex I.V. in Japan. Eiken was responsible for conducting clinical
trials and securing the necessary regulatory approvals in Japan. Under the terms
of the agreement, Eiken paid the Company license fees of $1,500,000. In
addition, Eiken pays royalties based upon sales. The agreement terminates on the
later of (i) the expiration of the last to expire technology patent or (ii) ten
years after the date all necessary approvals were obtained.
In 1990, the Company entered into a second manufacturing and distribution
agreement with Eiken, granting Eiken the exclusive right to manufacture and
distribute GastroMARK and Combidex in Japan. In addition, for a period of 180
days after the Company files an IND for any future Advanced Magnetics' MRI
contrast agents, Eiken has the right of first refusal to manufacture and
distribute such product in Japan. Upon execution of this agreement, Eiken paid
the Company a license fee of $1,000,000. Additionally, Eiken agreed to pay the
Company royalties on sales of all products sold by Eiken under the agreement.
The agreement is perpetual but terminable upon specified events such as
nonperformance, insolvency or assignment without consent. Due to market
conditions in Japan, Eiken has decided not to market GastroMARK or Combidex and
rights to these products in Japan have reverted back to the Company.
Additionally, Eiken has decided not to exercise its option to develop Code 7228
in Japan.
GUERBET. In 1987, the Company entered into a supply and distribution
agreement with Guerbet. Under this agreement, Guerbet has been appointed the
exclusive distributor of Feridex I.V. in western Europe (under the tradename
Endorem(TM)) and Brazil. Guerbet is responsible for conducting clinical trials
and securing the necessary regulatory approvals in the countries in its
territory. Guerbet paid the Company license fees and is required to pay
royalties based on sales. The Company is entitled to receive an additional
percentage of Guerbet's sales in return for selling to Guerbet its requirements
for the active ingredient used in Endorem. The agreement terminates on the later
of (i) the expiration of the last to expire technology patent or (ii) ten years
after the date all necessary approvals were obtained in France.
In 1989, the Company entered into a second supply and distribution
agreement with Guerbet granting Guerbet an exclusive right in western Europe and
Brazil to manufacture and sell GastroMARK (under the tradename Lumirem(TM)) and
any future Advanced Magnetics MRI contrast agents that Guerbet decides to
market. At this time Guerbet has taken the rights to Combidex (under the
tradename Sinerem(TM)) and Code 7228. Under the terms of this second
distribution agreement, Guerbet paid the Company a license fee in 1989. In
addition, Guerbet will pay the Company both royalties and a percentage of net
sales as the purchase price for the active ingredient of the licensed products.
The Company is required to sell to Guerbet its requirements for the active
ingredient used in the contrast agents. The agreement is perpetual but
terminable upon specified events such as nonperformance, insolvency or
assignment without consent.
MALLINCKRODT. In 1990, the Company entered into a manufacturing and
distribution agreement for GastroMARK with Mallinckrodt Inc. ("Mallinckrodt").
Under this agreement, Mallinckrodt received the exclusive right to manufacture
and co-market GastroMARK in the United States, Canada and Mexico. Under this
agreement, the Company reserved the right to sell the product through its own
direct sales personnel. Mallinckrodt has paid $1,350,000 in license fees and a
$500,000 non-refundable milestone payment upon FDA approval of the NDA.
Additionally, the Company receives royalties based on Mallinckrodt's GastroMARK
sales as well as a percentage of sales for supplying the active ingredient. The
agreement is perpetual but terminable upon specified events such as
nonperformance, insolvency or assignment without consent.
SQUIBB DIAGNOSTICS. In 1991, the Company entered into agreements with
Squibb Diagnostics, a division of Bristol-Myers Squibb Co. ("Squibb
Diagnostics") covering certain technology and the manufacturing and marketing of
certain contrast agents including Combidex, which agreements have been
terminated. Under agreements returning the products and technology rights to the
Company, the Company is obligated to pay Squibb Diagnostics up to a maximum of
$2,750,000 in royalties in connection with product sales of Combidex.
5
<PAGE> 7
MANUFACTURING AND SUPPLY ARRANGEMENTS
The Company's Cambridge, Massachusetts facility is registered with the FDA
and is subject to "current Good Manufacturing Practices" ("cGMP") as prescribed
by the FDA. The Company currently manufactures Feridex I.V. bulk product for
sale to Guerbet, manufactures Feridex I.V. finished product for sale to Berlex
and manufactures GastroMARK bulk product for sale to Guerbet and Mallinckrodt.
The Company intends to manufacture Combidex formulated drug product for
commercial use, subject to FDA approval, and Code 7228 finished product for
clinical use. The Company intends to use a contract manufacturer for final
manufacturing of Combidex.
PATENTS AND TRADE SECRETS
The Company considers the protection of its technology to be material to
its business. The Company's policy is to aggressively protect its competitive
technology position by a variety of means, including applying for patents in the
United States and in appropriate foreign countries. The Company has been granted
28 U.S. patents and has several patent applications pending. The Company has
filed counterpart patent applications in several foreign countries. In addition,
the Company is a party to various license agreements, including nonexclusive
cross-licensing arrangements covering MRI imaging technology with Nycomed
Imaging A.S. of Oslo, Norway ("Nycomed") and Schering AG ("Schering") of Berlin,
Germany. The Company's proprietary position depends in part on these licenses,
and termination of the licenses for any reason could have a material adverse
effect on the Company by limiting or prohibiting the commercial sale of its
products. Although the Company believes that further patents will be issued on
pending applications, no assurance to this effect can be given.
The patent positions of pharmaceutical and biopharmaceutical firms,
including Advanced Magnetics, are generally uncertain and involve complex legal
and factual questions. There can be no assurance that any claims which are
included in pending or future patent applications will be issued, that any
issued patents will provide the Company with competitive advantages or will not
be challenged by others, or that the existing or future patents of third parties
will not have an adverse effect on the ability of the Company to commercialize
its products.
The Company also intends to rely on its trade secrets, know-how, continuing
technological innovations and licensing opportunities to maintain and develop
its competitive position. Although the Company seeks to protect its proprietary
information, there can be no assurance that others will not independently
develop the same or similar information, design around its patents, obtain
unauthorized access to the Company's proprietary information or misuse
information to which the Company has granted access. Litigation may be necessary
to enforce any patents issued to the Company or to determine the scope of other
person's proprietary rights in court or administrative proceedings. Any
litigation or administrative proceeding could result in substantial costs to the
Company and distraction of the Company's management. An adverse ruling in any
litigation or administrative proceeding could have a material adverse effect on
the Company's business, financial condition and results of operations.
COMPETITION
The pharmaceutical and biopharmaceutical industries are subject to intense
competition and rapid technological change. Certain companies, including the
Company's collaborators, which have greater human and financial resources
dedicated to product development and clinical testing than the Company, are
developing MRI contrast agents. The Company's collaborators are not restricted
from developing and marketing competing products and, as a result of certain
cross-license agreements among the Company and certain of its competitors
(including one of its collaborators), the Company's competitors will be able to
utilize certain of the Company's technology in the development of competing
products. The Company may not be able to compete successfully with these
companies. In addition, further product and technological developments may make
other imaging modalities more compelling than MRI and adversely impact sales of
the Company's products.
6
<PAGE> 8
The Company believes that its ability to compete successfully in the MRI
contrast agent market will depend on a number of factors including the
implementation of effective marketing campaigns by the Company and/or its
marketing and distribution partners, development of efficacious products, timely
receipt of regulatory approvals and product manufacturing at commercially
acceptable costs. In addition, market acceptance of both MRI as an appropriate
technique for imaging certain organs and the Company's products as part of such
imaging is critical to the success of its contrast agent products. Although the
Company believes that its contrast agents offer advantages over competing MRI,
CT or X-ray contrast agents, there can be no assurance that there will be
greater acceptance of its products over other contrast agents. In addition, to
the extent that other diagnostic techniques such as CT and X-ray may be
perceived as providing greater value than MRI, any corresponding decrease in the
use of MRI could have an adverse effect on the demand for the Company's contrast
agent products. There can be no assurance that the Company will be able to
successfully market its products alone or with its partners, develop efficacious
products, obtain timely regulatory approvals, manufacture products at
commercially acceptable costs, gain satisfactory market acceptance or otherwise
successfully compete in the future.
There are several MRI contrast agents for imaging lesions of the liver on
the market and in various phases of human testing in the United States and
abroad. Schering has two products, Resovist, a carboxydextran superparamagnetic
iron oxide formulation, and Eovist, a chelated gadolinium compound. The Company
believes that Schering has filed for European approval of Resovist but the
status of Eovist in Europe is unknown. Schering has completed Phase III studies
of Resovist in the United States. The Company does not know the status of
Resovist or Eovist in Japan. Nycomed has received marketing approval in the
United States and Europe for its MnDPDP product Teslascan for MRI of liver
lesions. The Company believes that Bracco S.p.A. has filed for marketing
approval in Europe for Gadolinium BOPTA, a chelated gadolinium compound for MR
imaging of liver lesions. To the Company's knowledge there are no approved
products or drug candidates in human clinical development for the
contrast-enhanced imaging of lymph nodes.
In the area of oral contrast agents, Pharmacyclics, Inc. filed an NDA in
late 1995 for GADOLITE, its gadolinium-based product candidate which is
currently not approved by the FDA. Bracco S.p.A. has received marketing approval
in the United States for Lumenhance, its liposomal encapsulated oral manganese
compound which is not being marketed at this time. In October 1997, the FDA
approved Ferriseltz(R), an oral MRI agent from Oncomembrane Inc. The Company
does not know how Bracco or Oncomembrane are planning to market these products
in the future. These competitive products or other products developed by the
Company's competitors may be more effective than any products developed by the
Company or render the Company's technology obsolete. In addition, further
technological and product developments may make other imaging modalities more
competitive.
Many of these companies, as well as other imaging companies, have
substantially greater capital, research and development, manufacturing and
marketing resources and experience than the Company and represent significant
competition for Advanced Magnetics. Such companies may succeed in developing
technologies and products that are more effective or less costly than any that
may be developed by the Company and may also prove to be more successful than
the Company in production and marketing. Furthermore, products developed by the
Company's competitors may be more effective than any products developed by the
Company or render the Company's technology obsolete.
GOVERNMENT REGULATION AND REIMBURSEMENT
The production and marketing of the Company's products and its ongoing
research and development activities are subject to regulation for safety,
efficacy and quality by numerous governmental authorities in the United States
and other countries. Pharmaceutical products intended for therapeutic use or for
intravenous or oral administration in humans are principally governed by FDA
regulations in the United States and by comparable government regulations in
foreign countries. Various federal, state and local statutes and regulations
also govern or influence the research and development, manufacturing, safety,
labeling, storage, record-keeping, distribution and marketing of such products.
The process of completing pre-clinical and clinical testing and obtaining the
approval of the FDA and similar health authorities in foreign countries to
market a new drug product requires a significant number of years and the
expenditure of substantial resources.
7
<PAGE> 9
Failure to obtain requisite governmental approvals, failure to obtain approvals
of the scope requested or withdrawal or suspension by the FDA or foreign
authorities of any approvals will delay or preclude the Company or its licensees
or collaborators from marketing the Company's products or limit the commercial
use of the products and will have a material adverse effect on the Company's
business, financial condition and results of operations.
The steps required by the FDA before a new human pharmaceutical product
(including a contrast agent) may be marketed in the United States include: (a)
pre-clinical laboratory tests, in vivo pre-clinical studies and formulation
studies; (b) the submission to the FDA of a request for authorization to conduct
clinical trials subject to an Investigational New Drug ("IND") exemption, to
which the FDA must not object, before human clinical trials may commence; (c)
adequate and well-controlled human clinical trials to establish the safety and
efficacy of the drug for its intended use; (d) submission to the FDA of an NDA;
(e) approval and validation of manufacturing facilities used in production of
the pharmaceutical product; and (f) review and approval of the NDA by the FDA
before the drug product may be shipped or sold commercially.
Pre-clinical tests include the laboratory evaluation of product chemistry
and formulation, as well as animal studies to assess the potential safety and
efficacy of the product. Pre-clinical test results are submitted to the FDA as a
part of the IND. Clinical trials are typically conducted in three sequential
phases, although the phases may overlap. Phase I involves the initial
administration of the drug to a small group of humans, either healthy volunteers
or patients, to test for safety, dosage tolerance, absorption, distribution,
metabolism, excretion and clinical pharmacology and, if possible, early
indications of effectiveness. Phase II involves studies in a small sample of the
actual intended patient population to assess the preliminary efficacy of the
investigational drug for a specific clinical indication, to ascertain dose
tolerance and the optimal dose range and to collect additional clinical
information relating to safety and potential adverse effects. Once an
investigational drug is found to have some efficacy and an acceptable clinical
safety profile in the targeted patient population, Phase III studies can be
initiated to further establish safety and efficacy of the investigational drug
in a broader sample of the target patient population. The results of the
clinical trials together with the results of the pre-clinical tests and complete
manufacturing information are submitted in an NDA to the FDA for approval. The
FDA may suspend clinical trials at any point in this process if it concludes
that patients are being exposed to an unacceptable health risk.
Both before and after approval is obtained, a product, its manufacturer,
and the holder of the NDA for the product are subject to comprehensive
regulatory oversight. Violations of regulatory requirements at any stage,
including the pre-clinical and clinical testing process, the approval process,
or thereafter (including after approval) may result in various adverse
consequences, including the FDA's delay in approving or refusal to approve a
product, withdrawal of an approved product from the market, and/or the
imposition of criminal penalties against the manufacturer and/or NDA holder. In
addition, later discovery of previously unknown problems may result in
restrictions on such product, manufacturer, or NDA holder, including withdrawal
of the product from the market. Also, new government requirements may be
established that could delay or prevent regulatory approval of the Company's
products under development.
If an NDA is submitted to the FDA, the application may not be reviewed and
approved by the FDA in a timely manner, if at all. Among the conditions for NDA
approval is the requirement that a prospective manufacturer's manufacturing
procedures conform to cGMP requirements, which must be followed at all times. In
complying with those requirements, manufacturers (including a drug sponsor's
third-party contract manufacturers) must continue to expend time, money and
effort in the area of production and quality control to ensure compliance. Even
after initial FDA approval has been obtained, further studies, including post-
market studies, may be required to provide additional information. Results of
such post-market programs may limit or expand the further marketing of the
product. Even if initial marketing approval is granted, such approval may entail
limitations on the indicated uses for which a product may be used and impose
labeling requirements which may adversely impact the Company's ability to market
its products. Finally, product approvals may be withdrawn if compliance with
regulatory standards is not maintained or if problems occur following initial
marketing.
8
<PAGE> 10
Domestic manufacturing establishments are subject to periodic inspections
by the FDA in order to assess, among other things, cGMP compliance. To supply
product for use in the United States, foreign manufacturing establishments must
comply with cGMP and are subject to periodic inspection by the FDA or by
regulatory authorities in certain of such countries under reciprocal agreements
with the FDA. Failure to maintain compliance with cGMP regulations and other
applicable manufacturing requirements of various regulatory agencies could have
a material adverse effect on the Company's business, financial condition and
results of operations.
The Company is also subject to foreign regulatory requirements governing
development, manufacturing and sales of pharmaceutical products that vary widely
from country to country. Approval of a drug by applicable regulatory agencies of
foreign countries must be secured prior to the marketing of such a drug in those
countries. The regulatory approval process may be more or less rigorous from
country to country and the time required for approval may be longer or shorter
than that required in the United States.
The Company is subject to regulation under local, state and federal law
regarding occupational safety, laboratory practices, handling of chemicals,
environmental protection and hazardous substances control. The Company possesses
a Byproduct Materials License from the Nuclear Regulatory Commission ("NRC") for
receipt, possession, manufacturing and distribution of radioactive materials.
The Company holds Registration Certificates from the United States Drug
Enforcement Administration and the Commonwealth of Massachusetts Department of
Public Health for handling controlled substances. The Company is registered with
the United States Environmental Protection Agency ("EPA") as a generator of
hazardous waste. All hazardous waste disposal must be made in accordance with
EPA and Commonwealth of Massachusetts requirements. The Company is subject to
the regulations of the Occupational Safety and Health Act and has in effect a
safety program to assure compliance with these regulations.
In both the United States and foreign markets, the Company's ability to
commercialize its products successfully also depends in part on the extent to
which reimbursement for the costs of such products and related treatments will
be available from government health administration authorities, private health
insurers and other third-party payors. Significant uncertainty exists as to the
reimbursement status of newly approved health care products and products used
for indications not approved by the FDA. If adequate reimbursement levels are
not maintained by government and other third-party payors for the Company's
products and related treatments, the Company's business, financial condition and
results of operations may be materially adversely affected.
MAJOR CUSTOMERS
One customer, Guerbet, accounted for approximately 10% of the Company's
revenues in fiscal 1999. No other customer accounted for more than 10% of total
revenues in fiscal 1999.
EMPLOYEES
As of December 7, 1999, the Company had approximately 36 full-time
employees, 27 of whom were engaged in research and development. The Company's
success depends in part on its ability to recruit and retain talented and
trained scientific personnel. The Company has been successful to date in
obtaining such personnel, but may not be so in the future.
None of the Company's employees is represented by a labor union, and the
Company considers its relations with its employees to be excellent.
FOREIGN OPERATIONS
The Company has no foreign operations. Revenues in fiscal 1999, 1998 and
1997 from customers and licensees outside of the United States, principally in
Europe, amounted to 19%, 26% and 6%, respectively, of the Company's total
revenues.
9
<PAGE> 11
PRODUCT LIABILITY INSURANCE
The use of any of the Company's potential products in clinical trials and
the sale of any approved products may expose the Company to liability claims
resulting from the use of products or product candidates. These claims might be
made by customers (including corporate partners), clinical trial subjects,
patients, pharmaceutical companies or others. The Company maintains product
liability insurance coverage for claims arising from the use of its products
whether in clinical trials or approved commercial usage. However, coverage is
becoming increasingly expensive and the Company may not be able to maintain
insurance at a reasonable cost. The Company's insurance may not provide
sufficient amounts to protect the Company against liability that could have a
material adverse effect on the Company's business, financial condition and
results of operations. The Company may not be able to obtain commercially
reasonable product liability insurance for any product approved for marketing in
the future and insurance coverage and the resources of the Company may not be
sufficient to satisfy any liability resulting from product liability claims. A
product liability claim or series of claims brought against the Company could
have a material adverse effect on its business, financial condition and results
of operations, whether or not the plaintiffs in such claims ultimately prevail.
RESEARCH AND DEVELOPMENT
The Company is committed to internal research and development as a method
of producing new products, improving existing products and growing revenues. The
Company spent $7,952,331, $8,961,796 and $9,304,327 in each of the last three
fiscal years respectively on research and development.
ITEM 2. PROPERTIES:
The Company's principal pharmaceutical manufacturing and research and
development operations are located in a modern Company-owned building of
approximately 25,000 square feet in Cambridge, Massachusetts. The Company has
leased two additional premises in Cambridge of approximately 18,000 total square
feet to be used for manufacturing, warehousing and executive office space. One
lease expires on November 17, 2000 and the other lease expires on November 30,
2000. The lease expiring on November 30, 2000 is presently subleased through its
date of expiration. In addition, the Company leases premises of approximately
5,200 square feet in Princeton, New Jersey used by the Company's clinical
development group as a general business, sales and administrative office. This
lease expires on September 30, 2003. The Company believes these facilities are
adequate for its current and anticipated short-term needs and that it will be
able to enter into lease extensions or to lease comparable space, if necessary.
However, the acquisition and required regulatory approvals for additional
pharmaceutical manufacturing space can be time consuming and expensive. There is
no assurance that if the Company desired to expand its manufacturing capacity it
would be able to do so on a timely basis, if at all.
ITEM 3. LEGAL PROCEEDINGS:
The Company and certain of its officers were sued in an action entitled
David D. Stark, M.D. v. Advanced Magnetics, Inc., Jerome Goldstein, Ernest V.
Groman, and Lee Josephson, Civil Action No. 92-12157-WGY, in the United States
District Court for the District of Massachusetts on September 3, 1992. The
plaintiff, a former consultant to the Company, claims that he was incorrectly
omitted as an inventor or joint inventor on certain of the Company's patents and
on pending applications, and seeks injunctive relief and unspecified damages. In
addition, the complaint also alleges state law claims for breach of contract,
breach of good faith and fair dealing, breach of implied contract,
misappropriation of trade secrets, conversion, negligent misrepresentation,
misrepresentation, unjust enrichment and unfair trade practices. The District
Court has stayed this federal action pending resolution of an appeal in the
State Court of summary judgment in the Company's favor as well as resolution of
a jurisdictional issue. While the outcome of the action cannot be determined,
the Company believes the action is without merit and intends to defend the
action vigorously. The Company may not be able to successfully defend this
action and the failure by the Company to prevail for any reason could have an
adverse effect on its future business, financial condition and results of
operations.
10
<PAGE> 12
The Company and certain of its officers were sued in David D. Stark, M.D.
v. Advanced Magnetics, Inc., Jerome Goldstein, Ernest V. Groman and Lee
Josephson, Civil Action No. 93-02846-C, in the Superior Court Department of the
Massachusetts Trial Court for Middlesex County. This case involves claims of
breach of contract, breach of good faith and fair dealing, breach of implied
contract, unjust enrichment and unfair trade practices that were originally
dismissed by, but later remanded to, the Federal Court in the above-mentioned
action, as well as a new count alleging tortious interference with contractual
or advantageous relations. The Superior Court granted partial summary judgment
in the Company's favor and dismissed the unfair trade practices and tort counts.
The plaintiff's contract claims have been dismissed with prejudice and final
judgment was entered against the plaintiff. The plaintiff filed an appeal in
David D. Stark, M.D. v. Advanced Magnetics, Inc., Jerome Goldstein, Ernest V.
Groman and Lee Josephson, Appeal No. 98-P-1749 in the Massachusetts Appeals
Court, on January 25, 1999. While the outcome of the action cannot be
determined, the Company believes the action is without merit and intends to
defend the action vigorously. The Company may not be able to successfully defend
this action and the failure by the Company to prevail for any reason could have
an adverse effect on its future business, financial condition and results of
operations.
The Company filed suit on October 7, 1997 against Sanofi Pharmaceuticals,
Inc. (formerly known as Sanofi Winthrop, Inc.) and Sanofi SA (collectively,
"Defendants") in the Superior Court of the Commonwealth of Massachusetts. The
action is entitled Advanced Magnetics, Inc. v. Sanofi Pharmaceuticals, Inc. and
Sanofi SA, Civil Action No. 97-5222B. The Company claims that the Defendants
tortiously interfered with a license, supply and marketing agreement (the
"Agreement"), and seeks unspecified monetary damages. In addition, the Company
seeks a declaration that the Defendants do not have any rights under the
Agreement and that the Company has not breached the Agreement. Sanofi
Pharmaceuticals, Inc., filed counterclaims against the Company on February 4,
1998 seeking compensatory damages of $11,500,000 and multiple damages as a
result of the Company's alleged breach of the Agreement. Sanofi Pharmaceuticals,
Inc. also filed a motion to dismiss the Company's tortious interference claim,
which the Court denied on July 3, 1998. On October 26, 1998, the Company served
a motion for partial summary judgment which, among other things, requests
judgment in its favor on all of Sanofi Pharmaceuticals, Inc.'s counterclaims. On
November 13, 1998, the Company filed an amended complaint adding claims for
unfair competition and breach of contract against the Defendants. On November
23, 1998, Defendants answered the Company's amended complaint, and Sanofi
Pharmaceuticals, Inc. served a new set of counterclaims seeking compensatory
damages of $15,000,000 and multiple damages as a result of the Company's alleged
conduct. On December 18, 1998, the Court held a hearing on the Company's motion
for partial summary judgment. On June 15, 1999, the Court granted partial
summary judgment in favor of the Company and against the Defendants, declared
that the Company did not breach the Agreement, was not unjustly enriched, and
did not violate Mass. Gen. Laws ch. 93A, and dismissed Sanofi Pharmaceuticals,
Inc.'s counterclaims for breach of contract, unjust enrichment, conversion
account annexed and violation of Mass Gen. Laws ch. 93A. On October 29, 1999,
the Company served a motion for partial summary judgment which, among other
things, requests judgment in its favor on Sanofi Pharmaceuticals, Inc.'s
remaining counterclaims against the Company and for judgment in its favor on the
Company's breach of contract claim against Sanofi Pharmaceuticals, Inc. Also on
October 29, 1999, Sanofi Pharmaceuticals, Inc. served a motion for partial
summary judgment which, among other things, requests judgment in its favor on
the Company's remaining claims. While the final outcome of the remaining claims
and counterclaims cannot be determined, the Company will pursue its claims
vigorously, and believes that Sanofi Pharmaceuticals, Inc.'s remaining
counterclaims are equally without merit and intends to defend them vigorously.
The Company may not be able to successfully defend the counterclaims and the
failure by the Company to prevail for any reason could have an adverse effect on
its future business, financial condition or results of operations.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS:
No matters were submitted to a vote of the Company's security holders
during the quarter ended September 30, 1999.
11
<PAGE> 13
EXECUTIVE OFFICERS OF THE REGISTRANT
JEROME GOLDSTEIN, 60, is a founder of the Company and has been Chief
Executive Officer, Chairman of the Board of Directors and Treasurer since the
Company's organization in November 1981. Mr. Goldstein was a co-founder of
Clinical Assays, Inc., serving from 1972 to 1980 as Vice President and then as
President. Mr. Goldstein is the husband of Marlene Kaplan Goldstein, Secretary
of the Company.
LEONARD M. BAUM, 46, joined the Company in October 1994 as Senior Vice
President and has been President and Chief Operating Officer since May 1997.
From 1986 to 1994, Mr. Baum was employed as Senior Director, Worldwide
Regulatory Affairs/Drug Safety by Squibb Diagnostics. Mr. Baum is also a member
of the Board of Directors.
PAULA M. JACOBS, 55, joined the Company in January 1986 as Vice
President -- Development. From 1981 to 1986, Dr. Jacobs was employed at Seragen,
Inc., first as Production Manager and later as General Manager of the Research
Products Division.
DENNIS R. LAWLER, 45, joined the Company in February 1989 as Director of
Quality Control and has been Vice President -- Quality Control since January
1997. Prior to February 1989, Mr. Lawler was employed at CIS-US, first as Senior
Quality Control Analyst, then as a Production Manager and then as a Plant
Manager.
JEROME M. LEWIS, 50, joined the Company in April 1986 as a Senior Scientist
and has been Vice President -- Scientific Operations since February 1991. Prior
to April 1986, Dr. Lewis was employed as a senior scientist by Petroferm Ltd., a
biotechnology company.
MARIA A. LUCAS, 38, joined the Company in September 1994 as Director of
Operations and has been Vice President of Clinical Information since January
1998. Prior to September 1994, Ms. Lucas was employed at Squibb Diagnostics as
Senior Manager, Diagnostics Data Management.
JAMES A. MATHESON, 55, joined the Company in May 1996 as Vice
President -- Finance. Prior to May, 1996, Mr. Matheson was Controller of Diatech
Diagnostics, Inc.
MARIE R. MORRIS, 47, joined the Company in September 1994 as Director,
Clinical Affairs and has been Vice President of Clinical Affairs since January
1998. Prior to September 1994, Ms. Morris was employed at Squibb Diagnostics, as
Manager, Clinical Operations Research.
MARK C. ROESSEL, 49, joined the Company in January 1982 as Director of
Regulatory Affairs and has been Vice President -- Regulatory Affairs since
January 1995. Prior to January 1982, Mr. Roessel was Compliance Manager of the
Clinical Assays Division of Baxter International, Inc.
MARLENE KAPLAN GOLDSTEIN is a founder of the Company and has been Secretary
of the Company since the Company's organization in November 1981.
PART II
ITEM 5. MARKET FOR THE COMPANY'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS:
The Company's common stock is listed on the American Stock Exchange under
the symbol AVM.
The table below sets forth the high and low sales price of the Company's
common stock on the American Stock Exchange for the fiscal quarters of 1999 and
1998.
FISCAL QUARTER
----------------------------------
FIRST SECOND THIRD FOURTH
----- ------ ----- ------
1999 High................................. 11 1/4 7 3/4 5 5/8 5 1/4
Low..................................... 5 3 1/2 3 1/2 3 1/8
1998 High................................. 10 1/2 13 5/16 13 3/8 12
Low..................................... 8 1/2 8 7/8 10 5/16 6 3/8
On December 7, 1999 there were approximately 280 stockholders of record.
The Company believes that the number of beneficial holders of Common Stock
exceeds 2,000. The last reported sale price of the Common Stock on December 7,
1999 was $4.06 per share. The Company has never declared or paid a cash dividend
on its capital stock.
12
<PAGE> 14
ITEM 6. SELECTED FINANCIAL DATA:
The selected financial data set forth below has been derived from the
audited financial statements of the Company. This information should be read in
conjunction with the financial statements and notes thereto set forth elsewhere
herein.
<TABLE>
<CAPTION>
FOR THE YEARS ENDED SEPTEMBER 30,
-------------------------------------------------------------------
1999 1998 1997 1996 1995
----------- ----------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C>
Statement of Operations Data:
Revenues:
License fees........................................ $ -- $ -- $ 5,500,000 $ -- $ 5,000,000
Royalties........................................... 680,000 980,542 363,445 50,000 189,493
Product sales....................................... 1,966,059 1,399,871 1,580,357 12,762 2,120,457
Contract research and development................... 581,429 399,897 62,920 6,810 --
Interest, dividends and net gains and losses on
sales of securities............................... 4,202,568 3,623,836 3,495,049 1,761,450 2,287,311
----------- ----------- ----------- ----------- -----------
Total revenues................................ 7,430,056 6,404,146 11,001,771 1,831,022 9,597,261
Costs and Expenses:
Cost of product sales............................... 454,642 237,945 311,678 2,550 425,187
Contract research & development expenses............ 37,056 6,514 8,815 -- --
Company-sponsored research and development
expenses.......................................... 7,952,331 8,961,796 9,304,327 9,671,897 8,601,791
Charge (credit) for purchase of in-process research
and development*.................................. -- -- -- -- (380,000)
Selling, general & administrative expenses.......... 3,694,038 3,701,410 1,437,599 1,871,568 1,759,348
----------- ----------- ----------- ----------- -----------
Total costs and expenses...................... 12,138,067 12,907,665 11,062,419 11,546,015 10,406,326
Other Income:
Other income........................................ 265,593 -- 264,800 -- --
Gain on sale of in vitro product line**............. -- -- -- -- 3,404,527
----------- ----------- ----------- ----------- -----------
Income (loss) before provision for income taxes....... (4,442,418) (6,503,519) 204,152 (9,714,993) 2,595,462
Minority shareholder interest in subsidiary........... -- (194,178) -- -- --
Income tax (benefit) provision........................ -- -- (379,022) -- 400,000
----------- ----------- ----------- ----------- -----------
Income (loss) before cumulative effect of accounting
change.............................................. (4,442,418) (6,309,341) 583,174 (9,714,993) 2,195,462
Cumulative effect of accounting change................ -- -- -- -- 117,540
----------- ----------- ----------- ----------- -----------
Net income (loss)..................................... $(4,442,418) $(6,309,341) $ 583,174 $(9,714,993) $ 2,313,002
=========== =========== =========== =========== ===========
Net income (loss) per share before cumulative effect
of accounting change................................ $ (0.66) $ (0.93) $ 0.09 $ (1.44) $ 0.32
Cumulative effect of accounting change................ -- -- -- -- 0.02
----------- ----------- ----------- ----------- -----------
Basic and diluted income (loss) per share............. $ (0.66) $ (0.93) $ 0.09 $ (1.44) $ 0.34
=========== =========== =========== =========== ===========
Weighted average shares outstanding:
Basic............................................... 6,766,934 6,752,863 6,744,946 6,762,748 6,730,315
Diluted............................................. 6,766,934 6,752,863 6,813,984 6,762,748 6,870,839
----------- ----------- ----------- ----------- -----------
</TABLE>
- ---------------
* In August 1994, the Company reacquired the development and marketing rights
to the MRI contrast agent Combidex previously licensed to Squibb Diagnostics,
a Division of Bristol-Myers Squibb Company, Inc., and recorded a related
$760,000 charge for the purchase of in-process research and development. In
the first fiscal quarter of 1995, a credit for $380,000 was recorded to the
purchase of in-process research and development.
** On October 15, 1993, the Company sold its in vitro product line to PerSeptive
Biosystems, Inc. Under the terms of the agreement, PerSeptive Biosystems made
several payments to the Company from the years 1993 through 1995.
<TABLE>
<CAPTION>
AT SEPTEMBER 30
-------------------------------------------------------------------
1999 1998 1997 1996 1995
----------- ----------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C>
Balance sheet data:
Working capital....................................... $22,020,107 $27,278,502 $37,422,235 $33,605,818 $41,985,100
----------- ----------- ----------- ----------- -----------
Total assets.......................................... $27,816,359 $34,114,708 $44,976,181 $41,066,373 $50,843,222
----------- ----------- ----------- ----------- -----------
Stockholders' equity.................................. $27,054,709 $32,919,398 $43,423,058 $40,132,545 $49,071,072
</TABLE>
13
<PAGE> 15
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS:
OVERVIEW
Since its inception in November 1981, Advanced Magnetics, Inc., (the
"Company") has focused its efforts on developing its core superparamagnetic iron
oxide particle technology to develop magnetic resonance imaging ("MRI") contrast
agents. The Company has funded its operations with cash from license fees from
corporate partners, royalties, sales of its products, fees from contract
research performed for third parties, the proceeds of financings and income
earned on invested cash. The Company's success in the market for diagnostic
products will depend, in part, on the Company's ability to successfully develop,
test, produce and market its products; obtain necessary governmental approvals
in a timely manner; attract and retain key employees; and successfully respond
to technological and other changes in the marketplace.
The Company's operating results may continue to vary significantly from
quarter to quarter or from year to year depending on a number of factors
including: the timing of payments from corporate partners and research grants;
the introduction of new products by the Company; the timing and size of orders
from the Company's customers; and the acceptance of the Company's products. The
Company's current planned expense levels are based in part upon expectations as
to future revenue. Consequently, profits may vary significantly from quarter to
quarter or year to year based on the timing of revenue. Revenue or profits in
any period will not necessarily be indicative of results in subsequent periods
and there can be no assurance that the Company will achieve profitability or
grow revenue in the future.
A substantial portion of the Company's expenses consist of research and
development expenses. The Company expects its research and development expenses
to decrease in the near future as the clinical development of Combidex is
completed.
RESULTS OF OPERATIONS
Fiscal 1999 Compared to Fiscal 1998
Revenues
Total revenues for the fiscal year ended September 30, 1999 were $7,430,056
compared to $6,404,146 for the fiscal year ended September 30, 1998.
There were no license fee revenues for the fiscal years ended September 30,
1999 and 1998.
Royalties for the fiscal year ended September 30, 1999 were $680,000 as
compared to $980,542 in fiscal 1998. The majority of the decrease in royalties
is associated with the non-recurring product launch of Feridex I.V. in Japan
that occurred during the year ended September 30, 1998.
Product sales for the fiscal year ended September 30, 1999 were $1,966,059
compared to $1,399,871 for the fiscal year ended September 30, 1998. Product
sales in fiscal 1999 included an increase in sales of $697,548 at the Company's
former subsidiary, Kalisto Biologicals ("Kalisto"), offset by a decrease in
product sales by the Company of $131,360 primarily due to a decrease in sales of
the Company's product GastroMARK. See Note B to the Company's financial
statements for more information concerning Kalisto.
Contract research and development revenues were $581,429 during the fiscal
year ended September 30, 1999 compared with $399,897 in the fiscal year ended
September 30, 1998. The increase in fiscal year 1999 reflects the reimbursement
of certain development costs of approximately $473,000 under an agreement with
Berlex Laboratories, Inc. ("Berlex") to reimburse certain development costs
associated with Feridex I.V. and approximately $108,000 to provide development
services in the United States for one product from Guerbet S.A. ("Guerbet").
Interest, dividends and gains and losses on sales of securities resulted in
revenues of $4,202,568 for the fiscal year ended September 30, 1999 compared to
$3,623,836 for the fiscal year ended September 30, 1998. The increase was
primarily due to a net gain on sales of securities of $3,555,957 for the fiscal
year ended September 30, 1999 compared to a net gain of $2,473,826 for the
fiscal year ended September 30, 1998. Interest income for the fiscal year ended
September 30, 1999 was $534,733 compared to $978,546 for the
14
<PAGE> 16
fiscal year ended September 30, 1998 due to a decrease in interest-bearing
securities. Dividend income of $111,878 for the year ended September 30, 1999
was $59,587 less than the $171,464 for the fiscal year ended September 30, 1998.
Costs and Expenses
The cost of product sales for the fiscal year ended September 30, 1999 was
$454,642 compared to $237,945 for the fiscal year ended September 30, 1998. The
cost of product sales for fiscal 1999 was 23% of product sales and for fiscal
1998 was 17% of product sales. These changes are attributable to the increased
proportion of Kalisto product sales relative to sales of the Company's products
(prior to July 1, 1999) which have a higher cost of sales than the Company's
products. Contract sponsored research and development costs of $37,056 were
incurred during fiscal 1999, compared to $6,514 in fiscal 1998, and relate to
costs incurred providing development services to Guerbet.
Research and development expenses for the fiscal year ended September 30,
1999 were $7,952,331, a decrease of $1,009,465 compared to $8,961,796 for the
fiscal year ended September 30, 1998. The decrease was primarily attributable to
a reduction in direct, company-sponsored research and development programs.
Kalisto's expenditures for the nine-month period also decreased during the
fiscal year ended September 30, 1999. The Company expects that expenditures for
research and development for fiscal 2000 will continue to decrease.
Selling, general and administrative expenses for the fiscal year ended
September 30, 1999 were $3,694,038, compared to expenses of $3,701,410 for the
fiscal year ended September 30, 1998. Selling, general and administrative
expenses during the fiscal year ended September 30, 1999 included payments
related to reductions in the Company's workforce. The Company expects that
selling, general and administrative expenses for fiscal 2000 will continue to
decrease.
On July 1, 1999, the Company reduced its ownership in Kalisto. A loss on
the transaction of $155,967 was recognized in the fourth quarter of 1999 and is
included in other income on the Statement of Operations.
Income Taxes
There was no income tax provision or benefit for the fiscal year ended
September 30, 1999 and 1998.
Earnings
In the fiscal year ended September 30, 1999, the Company recorded a net
loss of ($4,442,418), or ($0.66) per share. In the fiscal year ended September
30, 1998, the Company recorded a net loss of ($6,309,341), or ($0.93) per share.
Fiscal 1998 Compared to Fiscal 1997
Revenues
Total revenues for the fiscal year ended September 30, 1998 were $6,404,146
compared to $11,001,771 for the fiscal year ended September 30, 1997.
There were no license fee revenues for the fiscal year ended September 30,
1998 and $5,500,000 in license fee revenues for the fiscal year ended September
30, 1997. The Company received a non-refundable milestone payment of $5,000,000
in October 1996 from Berlex, as a result of Berlex' market launch of Feridex
I.V. in the United States, under an agreement (the "Berlex Agreement") granting
Berlex a product license and exclusive marketing rights to the Company's Feridex
I.V. MRI contrast agent in the United States. The Company received a
non-refundable milestone payment of $500,000 in December 1996 from Mallinckrodt
Inc. ("Mallinckrodt") as a result of the FDA's marketing approval of GastroMARK
under an agreement (the "Mallinckrodt Agreement") granting Mallinckrodt a
product license and co-marketing rights to the Company's GastroMARK MRI contrast
agent in North America.
15
<PAGE> 17
Royalties for the fiscal year ended September 30, 1998 were $980,542 as
compared to $363,445 in fiscal 1997. Increased royalties in fiscal 1998 reflect
initiation of product sales in Japan of the Company's Feridex I.V. MRI contrast
agent by Eiken Chemical Co., Ltd. ("Eiken"); increased products sales in the
United States of Feridex I.V. by Berlex, increased product sales in North
America of GastroMARK oral MRI contrast agent by Mallinckrodt as well as
increased product sales in Europe by Guerbet of Feridex I.V. (under the trade
name Endorem) and GastroMARK (under the trade name Lumirem) as compared to
fiscal 1997.
Product sales for the fiscal year ended September 30, 1998 were $1,399,871
compared to $1,580,357 for the fiscal year ended September 30, 1997. These
results reflect substantial shipments in fiscal 1997 to Berlex to support the
Feridex I.V. launch offset in part by an increase in shipments to Guerbet during
fiscal 1998 as compared to fiscal 1997. Product sales in fiscal 1998 included
$220,853 in product sales from the Endochek Plus(TM) blood chemistry analyzer
for veterinary use launched by Kalisto.
Contract research and development revenues were $399,897 during the fiscal
year ended September 30, 1998 compared with $62,920 in the fiscal year ended
September 30, 1997. The increase in fiscal year 1998 reflects the reimbursement
of certain development costs of approximately $370,000 under the Berlex
Agreement.
Interest, dividends and gains and losses on sales of securities resulted in
revenues of $3,623,836 for the fiscal year ended September 30, 1998 compared to
$3,495,049 for the fiscal year ended September 30, 1997. The increase was
primarily due to a net gain on sales of securities of $2,473,826 for the fiscal
year ended September 30, 1998 compared to a net gain of $1,867,350 for the
fiscal year ended September 30, 1997. Interest income for the fiscal year ended
September 30, 1998 was $978,546 compared to $1,385,670 for the fiscal year ended
September 30, 1997. Dividend income of $171,464 for the year ended September 30,
1998 was $70,565 less than the $242,029 for the fiscal year ended September 30,
1997.
Costs and Expenses
The cost of product sales for the fiscal year ended September 30, 1998 was
$237,945 compared to $311,678 for the fiscal year ended September 30, 1997. The
cost of product sales for the fiscal year ended September 30, 1998 related to
the launch of the Endochek Plus(TM) system, a veterinary blood chemistry
analyzer, by Kalisto and the cost of contrast agent sales. The cost of product
sales for fiscal 1998 was 17% of product sales and for fiscal 1997 was 20% of
product sales. This change is attributable to changes in product mix and the
introduction of the Endochek Plus(TM) system.
Research and development expenses for the fiscal year ended September 30,
1998 were $8,961,796, a decrease of 4% compared to $9,304,327 for the fiscal
year ended September 30, 1997. The decrease was primarily attributable to a
reduction in direct, company-sponsored research and development programs and an
increase in collaborative research partnerships. The decreases were off-set by
$555,408 in R&D expenditures at Kalisto.
Selling, general and administrative expenses for the fiscal year ended
September 30, 1998 were $3,701,410, an increase of $2,263,811 from $1,437,599
for the fiscal year ended September 30, 1997. The increase was attributed to the
addition of Kalisto and increases in legal fees.
Income Taxes
There was no income tax provision for the fiscal year ended September 30,
1998 due to a net operating loss. There was an income tax benefit for the fiscal
year ended September 30, 1997 resulting from payments from the Internal Revenue
Service for contingent refunds.
Earnings
In the fiscal year ended September 30, 1998, the Company recorded a net
loss of ($6,309,341), or ($0.93) per share. In the fiscal year ended September
30, 1997, the Company recorded a net profit of $583,174, or $0.09 per share.
16
<PAGE> 18
LIQUIDITY AND CAPITAL RESOURCES
At September 30, 1999, the Company's cash and cash equivalents totaled
$17,052,636, compared with $7,704,245 at September 30, 1998. In addition, the
Company had marketable securities of $4,804,785 at September 30, 1999 as
compared to $19,096,942 on September 30, 1998. Net cash used in operating
activities was $6,733,531 in the fiscal year ended September 30, 1999, compared
to net cash used in operating activities of $8,981,704 in the fiscal year ended
September 30, 1998, a decrease of $2,248,173. The decrease in cash used in
operating activities was due primarily to a decrease of $1,866,923 in the net
loss on operations from $6,309,341 for the year ended September 30, 1998 to
$4,442,418 in the fiscal year ended September 30, 1999. Cash provided by
investing activities was $16,154,404 for the fiscal year ended September 30,
1999 compared to $5,927,801 provided by investing activities in the fiscal year
ended September 30, 1998. Cash provided by investing activities in the fiscal
year ended September 30, 1999 included the purchase of marketable securities of
$2,291,869. Proceeds from United States Treasury notes maturing was $7,500,000
and proceeds from the sale of marketable securities was $11,305,551 in the
fiscal year ended September 30, 1999. Cash provided by investing activities in
the fiscal year ended September 30, 1998 included the investment of $7,426,189
in marketable securities, offset by $5,000,000 from maturing United States
Treasury notes and $8,993,685 from the sale of marketable securities. Cash used
in financing activities was $72,482 for the fiscal year ended September 30, 1999
and included proceeds of $7,470 from the issuances of common stock offset by the
purchase of 17,900 shares of the Company's common stock on the open market for
$79,951. Cash provided by financing activities was $33,408 for the fiscal year
ended September 30, 1998 and included proceeds of $189,757 from the issuances of
common stock offset by the purchase of 16,800 shares of the Company's common
stock on the open market for $156,349. In May 1996, the Board of Directors
authorized the purchase of up to 250,000 shares of the Company's common stock on
the open market at prevailing market prices. This authorization was extended in
November 1997. To date, 122,200 shares have been purchased under this
authorization.
Capital expenditures in the fiscal year ended September 30, 1999 were
$280,891 compared to $584,360 in the fiscal year ended September 30, 1998. The
capital expenditures in both years continued the Company's efforts to upgrade
laboratory, production and computer equipment. The Company has no current
commitment for any significant expenditures on property, plant and equipment,
including purchases related to the Year 2000 compliance issue. The Company
expects that expenditures for research and development for fiscal 2000 will
decline.
Management believes that funds for future needs can be generated from
existing cash balances, cash generated from investing activities and cash
generated from operations. In addition, the Company will consider from time to
time various financing alternatives and may seek to raise additional capital
through equity or debt financing or to enter into corporate partnering
arrangements. However, funding may not be available on terms acceptable to the
Company, if at all.
IMPACT OF RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In June 1998, the FASB issued Statement No. 133 ("SFAS 133"), "Accounting
for Derivative Instruments and Hedging Activities" which is effective for fiscal
years beginning after June 15, 2000. The statement establishes accounting and
reporting standards requiring that every derivative instrument be recorded in
the balance sheet as either an asset or liability, measured at its fair value.
SFAS No. 133 also requires that changes in the derivative's fair value be
recognized currently in earnings unless specific hedge accounting criteria are
met. Adoption of this standard is not expected to have a material impact on the
financial position or results of operations of the Company.
CERTAIN FACTORS THAT MAY AFFECT FUTURE RESULTS
The Company does not provide forecasts of its future financial performance.
However, from time to time, information provided by the Company or statements
made by its employees may contain "forward looking" information that involves
risks and uncertainties. In particular, statements contained in this Form 10-K
that are not historical facts (including, but not limited to statements
contained in this Item 7 relating to liquidity
17
<PAGE> 19
and capital resources and the year 2000 issue) constitute forward looking
statements and are made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The Company's actual results of
operations and financial condition have varied and may in the future vary
significantly from those stated in any forward looking statements. Factors that
may cause such differences include, without limitation, the risks, uncertainties
and other information discussed below and within this Form 10-K, as well as the
accuracy of the Company's internal estimates of revenue and operating expense
levels. The following discussion of the Company's risk factors should be read in
conjunction with the financial statements and related notes thereto. Such
factors, among others, may have a material adverse effect upon the Company's
business, results of operations and financial condition.
No Assurance of Regulatory Approval. Prior to marketing, every product
candidate must undergo an extensive regulatory approval process in the United
States and in every other country in which the Company intends to test and
market its products. This regulatory process includes testing and clinical
trials of product candidates to demonstrate safety and efficacy and can require
many years and the expenditure of substantial resources in the United States and
in foreign countries in which approval is sought. Data obtained from preclinical
testing and clinical trials are subject to varying interpretations, which can
delay, limit or prevent FDA or foreign regulatory approval. In addition, changes
in FDA or foreign regulatory approval policies or requirements may occur or new
regulations may be promulgated which may result in delay or failure to receive
FDA or foreign regulatory approval. Delays and related costs in obtaining
regulatory approvals could have a material adverse effect on the Company's
business, financial condition and results of operations. Of the approximately
947 subjects who were administered Combidex during its product development, one
suffered an allergic reaction and died in January 1996. This death or any
subsequent death that may occur during the clinical trials for this product or
any of the Company's other product candidates may have an adverse effect on the
Company's ability to continue clinical trials or obtain regulatory approvals for
these product candidates and may otherwise have a material adverse effect on the
Company's business, financial condition and results of operations. Although the
Company has received approval in the United States and in certain foreign
countries to market Feridex I.V. and GastroMARK, regulatory approvals may not be
obtained for Combidex or any other products developed by the Company. Failure to
obtain requisite governmental approvals or failure to obtain approvals of the
scope requested could delay and may preclude the Company or its licensees or
other collaborators from marketing the Company's products or limit the
commercial use of the products and could have a material adverse effect on the
Company's business, financial condition and results of operations.
Regulatory approvals may entail limitations on the indicated uses of the
Company's products and impose labeling requirements which may adversely impact
the Company's ability to market its products. Even if regulatory approval is
obtained, a marketed product and its manufacturer are subject to continuing
regulatory review. Noncompliance with the regulatory requirements of the
approval process at any stage may result in various adverse consequences,
including the FDA's delay in approving or its refusal to approve a product,
withdrawal of an approved product from the market or, under certain
circumstances, the imposition of criminal penalties. Any such adverse
consequences could have a material adverse effect on the Company's business,
financial condition and results of operations.
Lack of Marketing and Sales History. Advanced Magnetics has limited
experience in marketing and selling its current products and product candidates
and relies on its corporate partners to market and sell Feridex I.V. and
GastroMARK and may do so for Combidex. In order to achieve commercial success
for any product candidate approved by the FDA for which the Company does not
have a marketing partner, the Company may have to develop a marketing and sales
force or enter into arrangements with others to market and sell its products.
Advanced Magnetics may not be successful in attracting and retaining qualified
marketing and sales personnel and may not be able to enter into marketing and
sales agreements with others on acceptable terms, if at all. Furthermore,
Advanced Magnetics or its corporate partners may not be successful in marketing
and selling the Company's products.
Uncertainty of Product Adoption and Development. The Company has not
generated significant revenues on royalties from the sale of its products by its
marketing partners. Although on the market since 1996 and 1997 respectively,
Feridex I.V. and GastroMARK still represent a new technology platform for
physicians to adopt. While the Company has completed human clinical testing of
Combidex, significant
18
<PAGE> 20
additional research and development efforts, including extensive human clinical
testing, may be required prior to approval of any regulatory application for
commercial sale. Code 7228 and any other product candidates will require
significant additional research and development efforts before submission of an
NDA or other regulatory filings for marketing approval. Products in early
clinical development are not expected to be commercially available for several
years, if at all. The development of new pharmaceutical products is highly
uncertain and the Company's development programs may not be completed
successfully, required regulatory approvals may not be obtained on a timely
basis, if at all, and products, including Combidex, Feridex I.V., or GastroMARK,
may not be commercially successful.
The Company's long-term viability and growth will depend on the successful
commercialization of Combidex, Feridex I.V., and GastroMARK and other products
resulting from its research activities. If any of the Company's development
programs are not completed successfully, required regulatory approvals are not
obtained or products for which approvals are obtained are not commercially
successful, the Company's business, financial condition and results of
operations could be materially adversely affected.
Need for Future Funding; Uncertainty of Access to Capital. The Company has
expended and will continue to expend substantial funds to complete the research,
development, clinical trials, regulatory approvals and other activities through
final commercialization of its products. It is possible that the Company may
need additional financing to satisfy its capital and operating requirements
relating to the development, manufacturing and marketing of its products. The
Company may seek such financing through arrangements with collaborative partners
and through public or private sales of the Company's securities, including
equity securities. The Company may not be able to obtain financing on acceptable
terms, if at all. Any additional equity financings could be dilutive to the
Company's stockholders. If adequate additional funds are not available, the
Company may be required to curtail significantly one or more of its research and
development programs or obtain funds through arrangements with collaborative
partners or others that may require the Company to relinquish rights to certain
of its products and product candidates on terms that it might otherwise find
unacceptable.
Uncertainties Relating to Clinical Trials; Technological
Uncertainty. Before obtaining regulatory approvals for the commercial sale of
any of its product candidates, the Company must demonstrate through extensive
preclinical testing and human clinical trials that the product is safe and
efficacious. The results from preclinical testing and early clinical trials of
products under development by the Company may not be predictive of results
obtained in subsequent clinical trials. Clinical trials are often conducted with
patients in the most advanced stages of disease. During the course of treatment,
these patients can die or suffer adverse medical effects for reasons that may
not be related to the product being tested, but which can nevertheless adversely
affect clinical trial results or approvals by the FDA. Clinical testing of
pharmaceutical products is itself subject to approvals by various governmental
regulatory authorities. Advanced Magnetics may not be permitted by regulatory
authorities to commence or continue clinical trials. Any delays in or
termination of the Company's clinical trial efforts could have a material
adverse effect on the Company's business, financial condition and results of
operations.
Many of the Company's products are subject to technological uncertainty.
Only two of the Company's products, Feridex I.V. and GastroMARK, have been
approved for sale in the United States. The Company's MRI contrast agents may
cause adverse reactions, including death, in certain persons under certain
conditions. These factors may adversely affect the development or
commercialization of the Company's products.
Dependence on Collaborative Relationships. The Company's strategy for the
development and commercialization of its product candidates has been to enter
into strategic alliances with various corporate partners, licensees, and other
collaborators. In some cases, the Company is dependent upon some of these
collaborators to conduct preclinical and clinical testing, to obtain FDA and
foreign regulatory approvals and to manufacture and market products. The Company
may not derive any revenues or profits from these activities and the Company may
not be able to enter into future collaborative relationships even if it desires
to do so. If any of the Company's collaborators breaches its agreement with the
Company or otherwise fails to perform, such event could have a material adverse
effect on the Company's business, financial condition and results of operations.
19
<PAGE> 21
Competition and Risk of Technological Obsolescence. The pharmaceutical and
biopharmaceutical industries are subject to intense competition and rapid
technological change. The Company has many competitors, many of which have
substantially greater capital and other resources than the Company and represent
significant competition for Advanced Magnetics. These companies may succeed in
developing technologies and products that are more effective or less costly than
any that may be developed by the Company, and may be more successful than the
Company in developing, manufacturing and marketing products. In addition, the
Company's MRI contrast agents represent a different approach to imaging certain
organs, and market acceptance of both MRI as an appropriate imaging technique
for such organs and the Company's products is critical to the Company's ability
to compete successfully. The Company may not be able to compete successfully in
the future. Developments by others may render the Company's products or product
candidates or technologies obsolete or noncompetitive. The Company's
collaborators or customers may choose to use competing technologies or products.
Uncertainty of Third-Party Reimbursement. In both the United States and
foreign markets, the Company's ability to commercialize its products may depend
in part on the extent to which reimbursement for the costs of such products and
related treatments will be available from government health administration
authorities, private health insurers and other third-party payors. In the United
States, there has been, and the Company expects that there will continue to be,
a number of federal and state proposals to reform the health care system.
Significant uncertainty exists as to the reimbursement status of both
newly-approved health care products and products used for indications not
approved by the FDA. If adequate reimbursement levels are not maintained by
government and other third-party payors for the Company's products and related
treatments, the Company's business, financial condition and results of
operations may be materially adversely affected.
Uncertainty Regarding Patents and Proprietary Rights. The patent positions
of pharmaceutical and biopharmaceutical firms, including Advanced Magnetics, are
generally uncertain and involve complex legal and factual questions. Because of
the substantial length of time and expense associated with bringing new products
through development and regulatory approval to the marketplace, the
pharmaceutical and biopharmaceutical industries place considerable importance on
obtaining patent and trade secret protection for new technologies, products and
processes. The Company may not be successful or timely in obtaining any patents
for which it submits applications. The breadth of the claims obtained may not
provide any significant protection of the Company's technology. The degree of
protection afforded by patents for licensed technologies or for future
discoveries may not be adequate to protect the Company's proprietary technology.
Moreover, patents issued to Advanced Magnetics may be contested, invalidated or
circumvented. Future patent interference proceedings involving patents of either
the Company or its licensors may have a material adverse effect on the Company's
business. Claims of infringement or violation of the proprietary rights of
others may be asserted against the Company. If Advanced Magnetics is required to
defend against such claims or to protect its own proprietary rights against
others, the Company may incur substantial costs which could have a material
adverse effect on the Company's business, financial condition and results of
operations.
In the future, Advanced Magnetics may be required to obtain additional
licenses to patents or other proprietary rights of others. Such licenses may not
be available on acceptable terms, if at all. The failure to obtain such licenses
could result in delays in marketing the Company's products or the inability to
proceed with the development, manufacturing or sale of product candidates
requiring such licenses. In addition, the termination of any of the Company's
existing licensing arrangements could have a material adverse effect on the
Company's business, financial condition and results of operations.
The Company also relies upon unpatented trade secrets and improvements,
unpatented know-how and continuing technological innovation to develop and
maintain its competitive position, which it seeks to protect, in part, by
confidentiality agreements with its corporate partners, collaborators, employees
and consultants. These agreements, however, may be breached. The Company may not
have adequate remedies for any such breach, and the Company's trade secrets
might otherwise become known or be independently discovered by its competitors.
In addition, the Company cannot be certain that others will not independently
develop substantially equivalent or superseding proprietary technology, or that
an equivalent product will not be
20
<PAGE> 22
marketed in competition with the Company's products, thereby substantially
reducing the value of the Company's proprietary rights.
Uncertainties in Manufacturing. The Company manufactures bulk Feridex I.V.
and GastroMARK as well as Feridex I.V. finished product for sale by its
marketing partners and intends to, pending FDA approval, manufacture Combidex
finished product in its Massachusetts facilities. These facilities are subject
to current Good Manufacturing Practices ("cGMP") regulations prescribed by the
FDA. The Company may not be able to continue to operate at commercial scale in
compliance with the cGMP regulations. Failure to operate in compliance with cGMP
regulations and other applicable manufacturing requirements of various
regulatory agencies could have a material adverse effect on the Company's
business, financial condition and results of operations. In addition, the
Company is dependent on contract manufacturers for the final production of
Combidex. In the event that the Company is unable to retain manufacturing for
this product, it will not be able to develop and commercialize it as planned.
The Company may not be able to enter into agreements for the manufacture of
future products with manufacturers whose facilities and procedures comply with
cGMP and other regulatory requirements or that such manufacturers will be able
to deliver required quantities of product that conform to specifications in a
timely manner.
Potential Product Liability; Uncertainties Related to Insurance. The use of
any of the Company's product candidates in clinical trials and the sale of any
approved products may expose the Company to liability claims resulting from the
use of products or product candidates. The Company maintains product liability
insurance coverage for claims arising from the use of its products in clinical
trials and commercial use. However, coverage is becoming increasingly expensive
and the Company may not be able to maintain insurance at a reasonable cost.
Furthermore, the Company's insurance may not provide sufficient coverage amounts
to protect the Company against liability that could have a material adverse
effect on the Company's business, financial condition and results of operations.
The Company presently maintains product liability insurance covering the sale of
Feridex I.V. and GastroMARK, but the Company may not be able to obtain
commercially reasonable product liability insurance for any product approved for
marketing in the future. Insurance coverage and the resources of the Company may
not be sufficient to satisfy any liability resulting from product liability
claims. A product liability claim or series of claims brought against the
Company could have a material adverse effect on its business, financial
condition and results of operations, whether or not the plaintiffs in such
claims ultimately prevail.
Attraction and Retention of Key Employees. Because of the specialized
nature of its business, Advanced Magnetics is highly dependent on its ability to
attract and retain qualified scientific and technical personnel for the research
and development activities conducted or sponsored by the Company. Furthermore,
the Company's possible expansion into areas and activities requiring additional
expertise, such as product distribution and marketing and sales, may require the
addition of new management personnel and the development of additional expertise
by existing management personnel. There is intense competition for qualified
personnel in the areas of the Company's activities, and the Company may not be
able to continue to attract and retain the qualified personnel necessary for the
development of its business. The failure to attract and retain such personnel or
to develop such expertise could adversely affect the Company's business,
financial condition and results of operations.
Volatility of Common Stock Price. The market prices for securities of
biopharmaceutical and pharmaceutical companies, including the Company, have
historically been highly volatile. Such fluctuations in operating results may
cause the market price of the Company's Common Stock to be volatile. In
addition, the market prices for securities of biopharmaceutical and
pharmaceutical companies have from time to time experienced significant price
and volume fluctuations that are unrelated to the operating performance of such
companies. Various factors and events, including announcements by the Company or
its competitors concerning technological innovations, new products, clinical
trial results, agreements with collaborators, governmental regulations,
developments in patent or other proprietary rights, public concern regarding the
safety of products developed by the Company or others, may have a significant
impact on the market price of the Company's Common Stock and dividend policy.
21
<PAGE> 23
Year 2000 Readiness Disclosure Statement
The widely publicized Year 2000 issue arose because many existing computer
programs use only the last two digits to define the applicable year. As a
result, such computer programs may misinterpret "00" as the year 1900 rather
than the year 2000. The consequences of such a misinterpretation could range
from a simple miscalculation to a system failure that might cause a disruption
of operations, including, among other things, a temporary inability to process
transactions, send invoices, or engage in similar normal business activities.
Since computer and microprocessor use is so widespread, the issue has become a
societal concern, the potential impact of which is not yet known.
Under the auspices of the Audit Committee, the Company assessed its
exposure to potential disruptions caused by the Year 2000 issue. In the first
phase of its readiness investigation, the Company identified its Clinical Data
Network (which tracks and analyzes the results of product trials in support of
FDA approvals) and its accounting system as mission-critical components that
required protection from Year 2000-related disruption. The Company, in order to
address Year 2000 concerns and as part of a general systems upgrade, has made
the necessary changes to both systems. The Company has obtained written
confirmation that the new software applications are Year 2000 compliant. The
Company's computer hardware platforms have been confirmed as Year 2000 compliant
by their manufacturers and the Company has completed testing of these systems.
In addition to evaluating its computer systems, the Company recognized that
the Year 2000 issue may impact machines or equipment that rely on embedded
microchips. The Company has evaluated and tested such equipment used in its
manufacturing facilities and believes that it does not have a material risk of
disruptions in manufacturing due to a Year 2000-related failure. The Company has
also evaluated its non-manufacturing equipment and determined that it does not
have a material risk of disruption to its non-manufacturing systems due to a
Year 2000-related failure.
In addition to the Company's critical systems, the Company recognized that
it relies on third party service providers and suppliers in the conduct of its
business and that there was a potential exposure to Year 2000-related business
disruptions as a result. For example, third party service providers handle the
payroll function for the Company, and the Company also relies on the services of
telecommunication companies, banks, and utility companies, among others.
The Company has contacted all of its significant service providers and
obtained assurances that they are addressing Year 2000 issues in a prudent
fashion. However, the Company, like all others, is subject to exposure to
disruptions in the generic systems that all businesses and consumers rely on
generally.
The Company has obtained assurances from its significant raw material
suppliers that there will be no interruption of service as a result of the Year
2000 issue, and to the extent that such assurances were not given, the Company
has devised contingency plans to ameliorate the potential negative effects in
the event of the unavailability of materials. The Company currently has
sufficient inventory levels in case of possible disruptions anywhere in its
supply chain.
A failure of any contingency plan developed by the Company may not prevent
a business interruption caused by one or more of the Company's third party
service providers or suppliers, and such a failure may have a material adverse
effect on the Company. In addition, the failure on the part of the accounting
systems of the Company's customers due to the Year 2000 issue could result in a
delay in the payment of invoices issued by the Company. A failure of the
accounting systems of a significant number of the Company's customers would have
a material adverse effect on the Company.
All expenses related to determining and addressing Year 2000 readiness have
been expensed as incurred and have amounted to roughly $75,000 to date. However,
if compliance efforts of which the Company is not currently aware are required
and are not completed on time, the Year 2000 issue could have a material adverse
impact on the Company.
Various statements in this discussion of Year 2000 issues are forward
looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements include statements of the
22
<PAGE> 24
Company's expectation and statements regarding expected Year 2000 compliance.
These forward looking statements are subject to various risk factors which may
materially affect the Company's efforts to achieve Year 2000 compliance. These
risk factors include the large number of vendors and customers with which the
Company interacts and the truth and accuracy of their statements to the Company.
The Company's assessment of the effect of Year 2000 on the Company are based, in
part, upon information received from third parties and the Company's reasonable
reliance on that information. Therefore, the risk that inaccurate information is
supplied by third parties upon which the Company reasonably relied must be
considered as a risk factor that might affect the Company's Year 2000 efforts.
The Company has attempted to reduce the risks by utilizing an organized
approach, extensive testing, and allowance of ample contingency time to address
issues identified by tests.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK:
The Company owns financial instruments that are sensitive to market risks
as part of its investment portfolio. The investment portfolio is used to
preserve the Company's capital until it is required to fund operations,
including the Company's research and development activities. None of these
market-risk sensitive instruments are held for trading purposes. The Company
does not own derivative financial instruments in its investment portfolio. The
investment portfolio contains instruments that are subject to a decline in
equity markets.
Equity Market Risk -- The Company's investment portfolio includes
publicly-traded stocks of domestic issuers. Assuming a decline of 10% in the
market for domestic stocks generally, the Company's equity investments may be
expected to decline a corresponding 10%, resulting in a hypothetical reduction
of the value of the net assets of the Company (as of September 30, 1999) of less
than 2% as compared to a hypothetical reduction of the value of the net assets
of the Company (as of September 30, 1998) of less than 3%. This change is due to
the reduction of the Company's holdings of marketable securities. The use of a
10% estimate in the decline of equity securities is strictly for estimation and
evaluation purposes only. The value of the Company's assets may rise or fall by
a greater amount depending on actual general market performances and the value
of individual securities owned by the Company.
ITEM 8. FINANCIAL STATEMENTS:
The Company's Financial Statements and related Report of Independent
Accountants are presented in the following pages. The financial statements filed
in this Item 8 are as follows:
Report of Independent Accountants
Financial Statements:
Balance Sheets -- September 30, 1999 and 1998
Statements of Operations -- for the years ended September 30, 1999, 1998
and 1997
Statements of Comprehensive Income -- for the years ended September 30,
1999, 1998 and 1997
Statements of Stockholders' Equity -- for the years ended September 30,
1999, 1998 and 1997
Statements of Cash Flows -- for the years ended September 30, 1999, 1998
and 1997
Reconciliation of Net Income (Loss) to Net Cash Used in Operating
Activities -- for the years ended September 30, 1999, 1998 and 1997
Notes to Financial Statements
23
<PAGE> 25
INDEX TO FINANCIAL STATEMENTS
Report of Independent Accountants........................................ 25
Balance Sheets -- September 30, 1999 and 1998............................ 26
Statements of Operations -- for the years ended September
30, 1999, 1998 and 1997................................................ 27
Statements of Comprehensive Income -- for the years ended
September 30, 1999, 1998, and 1997..................................... 28
Statements of Stockholders' Equity -- for the years ended
September 30, 1999, 1998 and 1997...................................... 29
Statements of Cash Flows -- for the years ended September
30, 1999, 1998 and 1997................................................ 30
Reconciliation of Net Income (Loss) to Net Cash Used in
Operating Activities -- for the years ended September 30,
1999, 1998 and 1997.................................................... 31
Notes to Financial Statements............................................ 32
24
<PAGE> 26
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Stockholders of Advanced Magnetics, Inc.:
In our opinion, the accompanying balance sheets and the related statements
of operations, comprehensive income, stockholders' equity and cash flows present
fairly, in all material respects, the financial position of Advanced Magnetics,
Inc. at September 30, 1999 and September 30, 1998, and the results of its
operations and its cash flows for each of the three years in the period ended
September 30, 1999 in conformity with generally accepted accounting principles.
These financial statements are the responsibility of the Company's management;
our responsibility is to express an opinion on these financial statements based
on our audits. We conducted our audits of these statements in accordance with
generally accepted auditing standards, which require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates made by
management, and evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable basis for the opinion expressed
above.
/s/ PRICEWATERHOUSECOOPERS LLP
Boston, Massachusetts
November 9, 1999
25
<PAGE> 27
ADVANCED MAGNETICS, INC.
BALANCE SHEETS
<TABLE>
<CAPTION>
SEPTEMBER 30,
----------------------------
1999 1998
------------ ------------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents................................... $ 17,052,636 $ 7,704,245
Marketable securities....................................... 4,804,785 19,096,942
Accounts receivables (net of allowance for doubtful accounts
of $166,577 at September 30, 1999 and $0 at September 30
1998)..................................................... 648,201 995,010
Inventories................................................. 80,480 448,630
Prepaid expenses............................................ 195,655 228,985
------------ ------------
Total current assets.............................. 22,781,757 28,473,812
Property, plant and equipment:
Land........................................................ 360,000 360,000
Buildings................................................... 4,610,827 4,497,005
Laboratory equipment........................................ 8,007,095 8,065,834
Furniture and fixtures...................................... 760,538 745,560
------------ ------------
13,738,460 13,668,399
Less -- accumulated depreciation and amortization........... (9,065,660) (8,331,740)
------------ ------------
Net property, plant and equipment........................... 4,672,800 5,336,659
Other assets................................................ 361,802 304,237
------------ ------------
Total assets...................................... $ 27,816,359 $ 34,114,708
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable............................................ $ 118,465 $ 422,993
Accrued expenses............................................ 581,534 720,266
Income taxes payable........................................ 61,651 52,051
------------ ------------
Total current liabilities......................... 761,650 1,195,310
Commitments and contingencies
Stockholders' equity:
Preferred stock, par value $.01 per share, authorized
2,000,000 shares; none issued............................. -- --
Common stock, par value $.01 per share, authorized
15,000,000 shares; issued and outstanding 6,752,027 shares
as of September 30, 1999 and 6,767,358 shares as of
September 30, 1998........................................ 67,521 67,674
Additional paid-in capital.................................. 44,205,370 44,277,698
Retained earnings (deficit)................................. (16,847,061) (12,404,643)
Accumulated other comprehensive income...................... (371,121) 978,669
------------ ------------
Total stockholders' equity........................ 27,054,709 32,919,398
------------ ------------
Total liabilities and stockholders' equity........ $ 27,816,359 $ 34,114,708
============ ============
</TABLE>
The accompanying notes are an integral part of the financial statements.
26
<PAGE> 28
ADVANCED MAGNETICS, INC.
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
FOR THE YEARS ENDED SEPTEMBER 30,
-----------------------------------------
1999 1998 1997
----------- ----------- -----------
<S> <C> <C> <C>
Revenues:
License fees........................................ $ -- $ -- $ 5,500,000
Royalties........................................... 680,000 980,542 363,445
Product sales....................................... 1,966,059 1,399,871 1,580,357
Contract research and development................... 581,429 399,897 62,920
Interest, dividends and net gains and losses on
sales of securities............................... 4,202,568 3,623,836 3,495,049
----------- ----------- -----------
Total revenues............................ 7,430,056 6,404,146 11,001,771
Costs and expenses:
Cost of product sales............................... 454,642 237,945 311,678
Contract research and development expenses.......... 37,056 6,514 8,815
Company-sponsored research and development
expenses.......................................... 7,952,331 8,961,796 9,304,327
Selling, general and administrative expenses........ 3,694,038 3,701,410 1,437,599
----------- ----------- -----------
Total costs and expenses.................. 12,138,067 12,907,665 11,062,419
Other income:
Other income...................................... 265,593 -- 264,800
----------- ----------- -----------
Income (loss) before provision for income taxes and
minority interest in subsidiary................... (4,442,418) (6,503,519) 204,152
Minority interest in subsidiary..................... -- (194,178) --
Income tax (benefit) provision...................... -- -- (379,022)
----------- ----------- -----------
Net income (loss)................................... $(4,442,418) $(6,309,341) $ 583,174
=========== =========== ===========
Basic and diluted net income (loss) per share....... $ (0.66) $ (0.93) $ 0.09
=========== =========== ===========
Weighted average shares outstanding:
Basic............................................. 6,766,934 6,752,863 6,744,946
----------- ----------- -----------
Diluted........................................... 6,766,934 6,752,863 6,813,984
----------- ----------- -----------
</TABLE>
The accompanying notes are an integral part of the financial statements.
27
<PAGE> 29
ADVANCED MAGNETICS, INC.
STATEMENTS OF COMPREHENSIVE INCOME
<TABLE>
<CAPTION>
FOR THE YEARS ENDED SEPTEMBER 30,
------------------------------------------
1999 1998 1997
----------- ------------ -----------
<S> <C> <C> <C>
Net income (loss).................................. $(4,442,418) $ (6,309,341) $ 583,174
Other comprehensive income:
Unrealized gains (losses) on securities.......... 2,206,167 (1,753,901) 5,256,843
Reclassification adjustment for gains included in
net income.................................... (3,555,957) (2,473,826) (1,867,350)
----------- ------------ -----------
Other comprehensive income (loss).................. (1,349,790) (4,227,727) 3,389,493
----------- ------------ -----------
Comprehensive income (loss)........................ $(5,792,208) $(10,537,068) $ 3,972,667
----------- ------------ -----------
</TABLE>
The accompanying notes are an integral part of the financial statements.
28
<PAGE> 30
ADVANCED MAGNETICS, INC.
STATEMENTS OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
FOR THE YEARS ENDED SEPTEMBER 30, 1997, 1998, 1999
--------------------------------------------------------------------------------
ACCUMULATED
COMMON STOCK ADDITIONAL RETAINED OTHER TOTAL
------------------- PAID-IN EARNINGS COMPREHENSIVE STOCKHOLDERS'
SHARES AMOUNT CAPITAL (DEFICIT) INCOME EQUITY
--------- ------- ----------- ------------ ------------- -------------
<S> <C> <C> <C> <C> <C> <C>
Balance at September 30, 1996.... 6,761,612 $67,616 $44,926,502 $ (6,678,476) $1,816,903 $40,132,545
========= ======= =========== ============ ========== ===========
Shares issued in connection with
the exercise of stock
options........................ 42,450 425 271,148 -- -- 271,573
Shares surrendered in connection
with the exercise of stock
options........................ (13,757) (138) (209,289) -- -- (209,427)
Shares issued in connection with
employee stock purchase plan... 11,621 116 117,183 -- -- 117,299
Common shares repurchased........ (61,300) (613) (860,986) -- -- (861,599)
Other comprehensive income....... -- -- -- -- 3,389,493 3,389,493
Net income....................... -- -- -- 583,174 -- 583,174
--------- ------- ----------- ------------ ---------- -----------
Balance at September 30, 1997.... 6,740,626 67,406 44,244,558 (6,095,302) 5,206,396 43,423,058
========= ======= =========== ============ ========== ===========
Shares issued in connection with
the exercise of stock
options........................ 39,846 399 163,456 -- -- 163,855
Shares surrendered in connection
with the exercise of stock
options........................ (2,190) (22) (28,722) -- -- (28,744)
Shares issued in connection with
employee stock purchase plan... 5,876 59 54,587 -- -- 54,646
Common shares repurchased........ (16,800) (168) (156,181) -- -- (156,349)
Other comprehensive income....... -- -- -- -- (4,227,727) (4,227,727)
Net loss......................... -- -- -- (6,309,341) -- (6,309,341)
--------- ------- ----------- ------------ ---------- -----------
Balance at September 30, 1998.... 6,767,358 67,674 44,277,698 (12,404,643) 978,669 32,919,398
========= ======= =========== ============ ========== ===========
Shares issued in connection with
the exercise of stock
options........................ 1,329 13 10,397 -- -- 10,410
Shares surrendered in connection
with the exercise of stock
options........................ (1,027) (10) (10,388) -- -- (10,398)
Shares issued in connection with
employee stock purchase plan... 2,267 23 7,435 -- -- 7,458
Common shares repurchased........ (17,900) (179) (79,772) -- -- (79,951)
Other comprehensive income....... -- -- -- -- (1,349,790) (1,349,790)
Net loss......................... -- -- -- (4,442,418) -- (4,442,418)
--------- ------- ----------- ------------ ---------- -----------
Balance at September 30, 1999.... 6,752,027 $67,521 $44,205,370 $(16,847,061) $ (371,121) $27,054,709
========= ======= =========== ============ ========== ===========
</TABLE>
The accompanying notes are an integral part of the financial statements.
29
<PAGE> 31
ADVANCED MAGNETICS, INC.
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
FOR THE YEARS ENDED SEPTEMBER 30,
--------------------------------------------
1999 1998 1997
------------ ------------ ------------
<S> <C> <C> <C>
Cash flows from operating activities:
Cash received from customers..................... $ 2,834,912 $ 1,637,449 $ 7,043,429
Cash paid to suppliers and employees............. (11,369,713) (12,686,577) (9,330,973)
Dividends and interest received.................. 670,440 1,139,685 1,441,441
Royalties received............................... 699,269 925,817 --
Net proceeds from insurance settlement........... 371,561 -- 264,800
Income taxes paid................................ -- (2,500) --
Tax refund....................................... 60,000 4,422 379,022
------------ ------------ ------------
Net cash used in operating activities............ (6,733,531) (8,981,704) (202,281)
Cash flows from investing activities:
Proceeds from sales of marketable securities..... 11,305,551 8,993,685 9,270,016
Proceeds from notes and bonds maturing........... 7,500,000 5,000,000 12,500,000
Purchase of marketable securities................ (2,291,869) (7,426,189) (20,380,048)
Capital expenditures............................. (280,891) (584,360) (533,590)
(Increase) decrease in other assets.............. (57,565) (55,335) (53,045)
Cash sold in sale of Kalisto..................... (20,823) -- --
------------ ------------ ------------
Net cash provided by investing activities........ 16,154,403 5,927,801 803,333
Cash flows from financing activities:
Proceeds from issuances of common stock, net..... 7,470 189,757 179,445
Purchase of treasury stock....................... (79,951) (156,349) (861,599)
------------ ------------ ------------
Net cash (used in) provided by financing
activities..................................... (72,481) 33,408 (682,154)
------------ ------------ ------------
Net (decrease) increase in cash and cash
equivalents.................................... 9,348,391 (3,020,495) (81,102)
Cash and cash equivalents at beginning of year... 7,704,245 10,724,740 10,805,842
------------ ------------ ------------
Cash and cash equivalents at end of year......... $ 17,052,636 $ 7,704,245 $ 10,724,740
============ ============ ============
</TABLE>
The accompanying notes are an integral part of the financial statements.
30
<PAGE> 32
ADVANCED MAGNETICS, INC.
RECONCILIATION OF NET INCOME (LOSS)
TO NET CASH USED IN OPERATING ACTIVITIES
<TABLE>
<CAPTION>
FOR THE YEARS ENDED SEPTEMBER 30,
-----------------------------------------
1999 1998 1997
----------- ----------- -----------
<S> <C> <C> <C>
Net income (loss)................................... $(4,442,418) $(6,309,341) $ 583,174
----------- ----------- -----------
Adjustments to reconcile net income (loss) to net
cash used in operating activities net of assets
disposed of:
Non-cash reduction in value of investment in
subsidiary........................................ 155,967 -- --
Provision for doubtful accounts..................... 166,577 -- --
Non-cash reduction in value of minority interest in
subsidiary........................................ -- 194,178 --
Minority interest in subsidiary..................... -- (194,178) --
Depreciation........................................ 817,299 999,622 1,112,539
Accretion of U.S. Treasury Notes discount........... (15,358) (52,574) (227,721)
(Increase) decrease in accounts receivable.......... 172,539 (448,203) (397,572)
(Increase) decrease in inventories.................. 368,150 (335,452) 68,988
(Increase) decrease in prepaid expenses............. 33,330 (4,117) (93,634)
Increase (decrease) in accounts payable and accrued
expenses.......................................... (443,260) (359,736) 619,295
Increase (decrease) in income taxes payable......... 9,600 1,923 --
Net realized (gains) on sales of marketable
securities........................................ (3,555,957) (2,473,826) (1,867,350)
----------- ----------- -----------
Total adjustments......................... (2,291,113) (2,672,363) (785,455)
----------- ----------- -----------
Net cash used in operating activities............... $(6,733,531) $(8,981,704) $ (202,281)
=========== =========== ===========
</TABLE>
The accompanying notes are an integral part of the financial statements.
31
<PAGE> 33
NOTES TO FINANCIAL STATEMENTS
A. SUMMARY OF ACCOUNTING POLICIES:
Business
Founded in November 1981, Advanced Magnetics, Inc., a Delaware Corporation
(the "Company") is a biopharmaceutical company engaged in the development and
manufacture of compounds utilizing the Company's core proprietary colloidal
superparamagnetic particle technology and core polysaccharide technology for
magnetic resonance imaging ("MRI"). The products developed by the Company are
diagnostic imaging agents for use in conjunction with MRI to aid in the
diagnosis of cancer and other diseases.
The Company is subject to risks common to companies in the industry
including, but not limited to, market acceptance of products, uncertainty of
product development and commercialization, development by the Company or its
competitors of new technological innovations, dependence on key personnel,
product liability, protection of proprietary technology, and compliance with FDA
government regulations.
Consolidation Policy
The Company consolidated its majority-owned subsidiary until the date of
divestiture as outlined in footnote B. All intercompany transactions until that
time have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make certain estimates and
assumptions that effect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expenses during the reported
period. Actual results could differ from those estimates.
Cash and Cash Equivalents
Cash and cash equivalents consist of cash on hand, money market funds and
marketable securities having a maturity of less than three months at the date
acquired. Substantially all of the cash and cash equivalents at September 30,
1999 and 1998 were held in a money market account.
Marketable Securities
The Company's current portfolio consists of securities classified as
available-for-sale which are recorded at fair market value. The fair values of
marketable securities are based on quoted market prices. Net unrealized gains
and losses on marketable securities are recorded as a separate component of
stockholders' equity. Interest income is accrued as earned. Dividend income is
accrued on the ex-dividend date, and net realized gains and losses are computed
on the basis of average cost and are recognized when realized.
Inventories
Inventories are stated at the lower of cost (determined on a first-in,
first-out basis) or market.
Property, Plant and Equipment
Property, plant and equipment are stated at cost. The cost of additions and
improvements is charged to the property accounts while maintenance and repairs
are expensed as incurred. Upon sale or other disposition of property and
equipment, the cost and related depreciation are removed from the accounts and
any resulting gain or loss is reflected in income.
32
<PAGE> 34
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
Depreciation
Depreciation is recorded by the straight line method based on rates
sufficient to provide for retirement over estimated useful lives as follows:
buildings -- 40 years; laboratory equipment and furniture and fixtures -- 5
years; and leasehold improvements -- over the life of the lease.
Revenue Recognition
Revenue is recognized when products are shipped, when contract objectives
are achieved or when research activities are performed. License and royalty
revenues are accrued as earned.
Other Income
Other income includes amounts for gains in insurance settlements, loss on
sale of subsidiary and other items.
Income Taxes
The provision (benefit) for income taxes includes federal and state income
taxes currently payable and deferred income taxes arising from the recognition
of certain income and expenses in different periods for financial and tax
reporting purposes.
Income (Loss) per Share
Basic earnings per share is based upon the weighted average number of
common shares outstanding during the period. Diluted earnings per share is based
upon the weighted average number of common shares plus additional weighted
average common equivalents shares outstanding during the period when the effect
is not anti-dilutive. The weighted average common and common equivalent shares
used in the computation of basic and diluted earnings per share is presented
below. Aggregate options of 473,833 (weighted average exercise price of $9.57)
and 408,649 options (weighted average exercise price of $11.30) for 1999 and
1998, respectively, have not been included in the calculation of weighted
average shares since their effect would be anti-dilutive, given the net loss in
both years. In 1997, aggregate options of 5,050 (weighted average exercise price
of $16.98) have not been included in the calculation of weighted average shares
since they were "out of the money" and their effect would be anti-dilutive.
<TABLE>
<CAPTION>
FOR THE YEARS ENDED SEPTEMBER 30,
----------------------------------------
1999 1998 1997
----------- ----------- ----------
<S> <C> <C> <C>
Numerator:
Net income (loss)............................ $(4,442,418) $(6,309,341) $ 583,174
=========== =========== ==========
Denominator:
Weighted average number of common shares
issued and outstanding..................... 6,766,934 6,752,863 6,744,946
Assumed exercise of options reduced by the
number of shares which could have been
purchased with the proceeds of those
options.................................... -- -- 69,038
----------- ----------- ----------
Weighted average common and common equivalent
shares..................................... 6,766,934 6,752,863 6,813,984
Basic and diluted net income (loss) per
share...................................... $ (0.66) $ (0.93) $ 0.09
</TABLE>
Reclassifications
Certain amounts from the prior year have been reclassified to conform to
the current year's presentation.
33
<PAGE> 35
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
B. DE-CONSOLIDATION OF KALISTO BIOLOGICALS INC.:
On July 1, 1999, the Company reduced its ownership in Kalisto Biologicals
Inc. Terms of the transaction included the Company relinquishing control of
Kalisto by the resignation of the Company's representatives from Kalisto's Board
of Directors and the sale by Advanced Magnetics of approximately 63% of
Kalisto's stock to Kalisto's founder. The Company retains a 19.5% ownership
position in Kalisto. Accordingly, Kalisto was no longer consolidated with
Advanced Magnetics as of July 1, 1999 and is accounted for under the cost method
of accounting because the Company no longer has the ability to exercise
significant influence over the operating and financial policies of Kalisto.
Kalisto generated revenues of $918,402 and net losses of $(965,676) for the nine
months ended June 30, 1999. Kalisto generated revenues of $227,098 and net
losses of $(1,382,806) for the year ended September 30, 1998. Kalisto was not a
subsidiary of the Company in 1997. Kalisto had net assets of $(1,341,311) as of
June 30, 1999. A loss on the transaction of $155,967 was recognized in the
fourth quarter of 1999, and is included in other income on the Statement of
Operations.
C. MARKETABLE SECURITIES:
The cost and fair value of the marketable securities portfolio at September
30 are as follows:
<TABLE>
<CAPTION>
1999 1998
1999 COST FAIR VALUE 1998 COST FAIR VALUE
---------- ---------- ----------- -----------
<S> <C> <C> <C> <C>
U.S. government securities due in one
year or less.......................... $ -- $ -- $ 7,484,642 $ 7,513,215
Corporate bonds......................... -- -- 482,403 582,500
Preferred stock......................... -- -- 543,003 570,000
Common stock............................ 5,175,906 4,804,785 9,608,225 10,431,227
---------- ---------- ----------- -----------
Totals........................ $5,175,906 $4,804,785 $18,118,273 $19,096,942
========== ========== =========== ===========
</TABLE>
At September 30, 1999, gross unrealized holding losses were $371,121. At
September 30, 1998, gross unrealized holding gains were $978,669. For the fiscal
years ended September 30, 1999 and 1998, the net unrealized holding gains have
been recorded as a separate component of stockholders' equity.
During the year ended September 30, 1999, gross realized gains and gross
realized losses on the sale of marketable securities were $4,796,165 and
$1,240,208, respectively, resulting in a net realized gain of $3,555,957. During
the year ended September 30, 1998, gross realized gains on the sale of
marketable securities were $2,473,826. During the year ended September 30, 1997,
gross realized gains and gross realized losses on the sale of marketable
securities were $1,932,504 and $65,154, respectively, resulting in a net
realized gain of $1,867,350. Proceeds from U.S. treasury notes maturing were
$7,500,000, $5,000,000 and $12,500,000 in 1999, 1998 and 1997 respectively.
Interest, dividends and net gains (losses) on sales of securities consist
of the following:
<TABLE>
<CAPTION>
FOR THE YEARS ENDED SEPTEMBER 30,
--------------------------------------
1999 1998 1997
---------- ---------- ----------
<S> <C> <C> <C>
Interest income................................ $ 534,733 $ 978,546 $1,385,670
Dividend income................................ 111,878 171,464 242,029
Net gains on sales of securities............... 3,555,957 2,473,826 1,867,350
---------- ---------- ----------
Totals............................... $4,202,568 $3,623,836 $3,495,049
========== ========== ==========
</TABLE>
D. INVENTORIES:
The Company's inventories consisted entirely of raw materials of $80,480 on
September 30, 1999 and $448,630 on September 30, 1998.
34
<PAGE> 36
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
E. COMMITMENTS:
The Company leases laboratory, office and warehouse space under various
agreements. Rental expense for the years ended September 30, 1999, 1998 and 1997
amounted to $411,245, $572,729 and $339,311, respectively. Future minimum lease
payments for fiscal 2000, 2001, 2002, 2003 and 2004 amount to $417,611,
$189,092, $148,623, $151,210 and $37,964, respectively. The Company is also a
guarantor on a lease for office space for Kalisto in the event Kalisto defaults
on its obligations.
F. ACCRUED EXPENSES:
Accrued expenses consist of the following at September 30:
1999 1998
-------- ----------
Salaries and other compensation...................... $208,149 $ 249,234
License and royalty fees............................. 20,000 29,540
Clinical trials...................................... 116,649 177,722
Professional fees.................................... 164,000 169,000
Other................................................ 72,736 94,770
-------- ----------
Totals..................................... $581,534 $ 720,266
======== ==========
G. INCOME TAXES:
Deferred tax assets and deferred tax liabilities are recognized based on
temporary differences between the financial reporting and tax basis of assets
and liabilities using statutory rates. A valuation allowance is recorded against
deferred tax assets if it is more likely than not that some or all of the
deferred tax assets will not be realized.
The income tax (benefit) provision consisted of the following:
FOR THE YEARS ENDED SEPTEMBER 30,
---------------------------------
1999 1998 1997
-------- -------- ---------
Currently payable:
Federal................................... $ -- $ -- $(379,022)
State..................................... -- -- --
-------- -------- ---------
$ -- $ -- $(379,022)
-------- -------- ---------
Deferred:
Federal................................... -- -- --
State..................................... -- -- --
-------- -------- ---------
-- -- --
-------- -------- ---------
$ -- $ -- $(379,022)
======== ======== =========
35
<PAGE> 37
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
The provisions for income taxes were at different rates than the U.S.
statutory rates for the following reasons:
<TABLE>
<CAPTION>
FOR THE YEARS ENDED SEPTEMBER 30,
----------------------------------
1999 1998 1997
------- ------- --------
<S> <C> <C> <C>
U.S. federal statutory tax (benefit) rate.............. (34.0)% (34.0)% 34.0%
Dividends received deductions.......................... (0.6) (0.6) (31.0)
Prior years income tax refunds......................... -- -- (186.1)
Other, including a prior year tax adjustment........... (0.2) (0.1) (2.6)
Losses without tax benefit............................. 34.8 34.7 --
Tax benefit of temporary differences................... -- -- --
----- ----- ------
--% --% (185.7)%
===== ===== ======
</TABLE>
The $379,022 tax benefit recorded in fiscal 1997 is due to refunds of
alternative minimum taxes paid in prior years.
The components of the deferred tax assets and liabilities at September 30,
were as follows:
<TABLE>
<CAPTION>
1999 1998
------------ ------------
<S> <C> <C>
ASSETS
Net operating loss carryforwards...................... $ 9,397,988 $ 7,645,130
Research and experimentation tax credit
carryforward....................................... 3,004,518 2,511,022
Deductible intangibles................................ 102,016 111,370
Other................................................. 316,120 248,310
LIABILITIES
Property, plant and equipment depreciation............ (200,415) (246,347)
Other................................................. (70,142) (77,245)
------------ ------------
12,550,085 10,192,240
Valuation allowance................................... (12,550,085) (10,192,240)
------------ ------------
Net deferred taxes...................................... $ -- $ --
============ ============
</TABLE>
Due to the uncertainty surrounding the realization of the favorable tax
attributes in future tax returns, the Company has placed a valuation allowance
against its otherwise recognizable net deferred tax assets. Realization of
favorable tax attributes is, therefore, reflected as a tax benefit in the
provision for income taxes.
At September 30, 1999, the Company had unused net operating loss (NOL)
carryforwards for federal income tax purposes of approximately $23,227,000 which
expire through fiscal 2019. The Company also has federal research and
experimentation credits of approximately $2,541,000 which expire through fiscal
2014.
H. STOCK PLANS:
The Company's 1993 Stock Plan (the "1993 Stock Plan") provides for the
grant of options to the Company's directors, officers, employees and consultants
to purchase up to an aggregate of 700,000 shares of common stock. The maximum
term of the options under the 1993 Stock Plan is ten years. The number of shares
available for future grants at September 30, 1999 was 206,875.
The Company's 1983 Stock Option Plan (the "1983 Stock Plan") does not allow
for option grants after June 1993. The 1983 Plan provided for the grant of
options to purchase up to 900,000 shares of common stock at a price equal to the
fair market value of the stock at the date of grant to the Company's employees
and mandatory grants to outside directors upon initial election to the Board of
Directors. The maximum terms of incentive stock options and non-statutory
options under the 1983 Plan are ten years and ten years plus thirty days,
respectively.
36
<PAGE> 38
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
The Company has also granted to certain scientific advisors non-statutory
options to purchase a total of 32,625 shares of common stock at a price equal to
fair market value at the date of grant. As of September 30, 1999, 29,625 of
these options have been exercised.
On November 5, 1991, the Company's Board of Directors adopted the 1992
Non-Employee Director Stock Option Plan (the "1992 Plan") which the shareholders
approved. This plan provides for the grant to each non-employee director on
November 5, 1991, and each fifth anniversary thereafter, of an option to
purchase 5,000 shares of common stock up to an aggregate of 100,000 shares at a
price equal to the fair market value of the stock at the date of the grant,
vesting over a five year period. Under this plan, options to purchase 30,000
shares of common stock at a price of $21.00 per share and an additional 30,000
shares of common stock at a price of $15.25 per share were granted on November
5, 1991 and 1996, respectively. The 1992 Plan also provided for the grant of
options for 5,000 shares to new members of the Board of Directors. A total of
10,000 stock options were granted to new directors during fiscal year 1997 under
the 1992 Plan. No grants may be made under this plan after November 4, 2001.
On November 10, 1992, the Company's Board of Directors adopted the 1993
Non-Employee Director Stock Option Plan (the "1993 Plan") which the shareholders
approved. This plan provides for the grant to each non-employee director on
November 10, 1992, and each sixth anniversary thereafter an option to purchase
5,000 shares of common stock up to an aggregate of 100,000 shares at a price
equal to the fair market value of the stock at the date of the grant, vesting
over a five year period. The 1993 Plan also provided for the grant of options
for 5,000 shares to new members of the Board of Directors. Under this plan,
options to purchase 30,000 shares of common stock at a price of $14.50 per share
in fiscal year 1993 and an additional 25,000 shares of common stock at a price
of $9.625 per share were granted in fiscal year 1999. 5,000 stock options at a
price of 11.75 and 5,000 stock options at a price of 13.50 were granted to new
directors during fiscal year 1997 under the 1993 Plan. No grants may be made
under this plan after November 10, 2002.
During the fiscal year ended September 30, 1997, the Company's Board of
Directors approved the exchange of stock options by the Company's employees and
directors at the fair market value of the stock at the effective date of the
exchange. This provided for the cancellation of any unexercised stock options
and the reissuance of an equal number of stock options at the new price, with
50% of any previously vested options vesting immediately. The stock options
canceled were originally issued under the 1983 and 1993 Stock Plans and the 1992
and 1993 Non-Employee Director Stock Option Plans and were reissued under the
1993 Stock Plan. 236,825 options were exchanged effective on July 3, 1997 at an
exercise price of $11.50. 110,000 options were exchanged effective on August 5,
1997 at an exercise price of $11.125.
The Company adopted the disclosure provision of SFAS 123, "Accounting for
Stock-Based Compensation" ("FAS 123") in 1997 and has applied APB opinion 25 and
related interpretations in accounting for its Plans.
37
<PAGE> 39
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
Stock option activity for the years ended September 30, 1999, 1998 and 1997
is as follows:
<TABLE>
<CAPTION>
1999 1998 1998
------------------ ------------------ -------------------
WEIGHTED WEIGHTED WEIGHTED
AVERAGE AVERAGE AVERAGE
EXERCISE EXERCISE EXERCISE
SHARES PRICE SHARES PRICE SHARES PRICE
------- -------- ------- -------- -------- --------
<S> <C> <C> <C> <C> <C> <C>
Outstanding at beginning of year........ 408,649 $11.30 460,195 $10.73 407,645 $13.86
Granted................................. 144,000 $ 5.04 13,500 $11.88 475,825 $12.17
Exercised............................... (1,329) $ 7.83 (39,846) $ 4.11 (42,450) $ 6.40
Canceled................................ (77,487) $10.28 (25,200) $12.58 (380,825) $16.45
------- ------ ------- ------ -------- ------
Outstanding at end of year.............. 473,833 $ 9.57 408,649 $11.30 460,195 $10.66
======= ====== ======= ====== ======== ======
Options exercisable at year-end......... 169,620 $11.33 135,392 $11.04 98,070 $ 8.01
======= ====== ======= ====== ======== ======
Weighted average fair value of options
granted during the year............... $ 2.38 $ 6.16 $ 5.63
======= ======= ========
</TABLE>
The fair value of each option granted during 1999, 1998 and 1997 was
estimated on the date of grant using the Black-Scholes option-pricing model with
the following weighted average assumptions: (1) expected life of 5.0 years in
1999, 7.1 years in 1998 and 6.0 years in 1997 (2) expected volatility of 47.6%
in 1999, 37.5% in 1998 and 36 % in 1997 (3) risk-free interest rates of 5.38%
and 4.74% in 1999, 6.34% in 1998 and 6.2 % in 1997 and (4) no dividend yield.
The following table summarizes information about stock options outstanding
and exercisable at September 30, 1999:
<TABLE>
<CAPTION>
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
------------------------------------------ ----------------------
WEIGHTED WEIGHTED
WEIGHTED AVERAGE AVERAGE
RANGE OF NUMBER AVERAGE REMAINING EXERCISE NUMBER EXERCISE
EXERCISE PRICES OUTSTANDING CONTRACTUAL LIFE PRICE EXERCISABLE PRICE
- --------------- ----------- ----------------- -------- ----------- --------
<S> <C> <C> <C> <C> <C>
$4.00 - $ 6.00 119,000 9.6 $ 4.08 0 $ 0.00
$6.01 - $ 9.00 6,208 0.4 $ 7.43 6,208 $ 7.38
$9.01 - $12.24 348,625 7.4 $11.38 163,412 $11.48
- -------------- ------- ---- ------ ------- ------
$4.00 - $12.24 473,833 7.59 $10.55 169,620 $11.33
======= ==== ====== ======= ======
</TABLE>
Employee Stock Purchase Plan
The Company's 1997 Employee Stock Purchase Plan (the "Purchase Plan")
provides for the issuance of up to 150,000 shares of common stock to employees
of the Company. Under the terms of the Purchase Plan, eligible employees may
purchase shares in five annual offerings ending in 2002, through payroll
deductions of up to a maximum of 10% of the employee's earnings, at a price
equal to the lower of 85% of the fair market value of the stock on the
applicable annual offering commencement date of June 1 or termination date of
May 31. The first offering under the Purchase Plan ended on May 31, 1998 and
5,876 shares of common stock were purchased by eligible employees at a price of
approximately $9.30 per share. The second offering under the Purchase Plan ended
on May 31, 1999 and 2,267 shares of common stock were purchased by eligible
employees at a price of approximately $3.29 per share. As of September 30, 1999,
8,143 shares have been issued under this plan.
Had the Company adopted SFAS 123, the weighted average fair value for each
purchase right granted during fiscal 1999, 1998 and 1997 would have been $1.57,
$3.45 and $3.68, respectively.
38
<PAGE> 40
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
Pro Forma Disclosures
Had compensation cost for the Company's 1999, 1998 and 1997 grants for
stock-based compensation plans been determined consistent with SFAS 123, the
Company's net income (loss) and net income (loss) per share for 1999, 1998 and
1997 would approximate the pro forma amounts below:
<TABLE>
<CAPTION>
1999 1998 1997
----------- ----------- --------
<S> <C> <C> <C> <C>
Net income (loss)......................... As reported $(4,442,418) $(6,309,341) $583,174
Pro forma $(4,902,679) $(6,933,323) $276,163
Net income (loss) per share............... As reported $ (0.66) $ (0.93) $ 0.09
Pro forma $ (0.72) $ (1.03) $ 0.04
</TABLE>
The effects of applying SFAS 123 in this pro-forma disclosure are not
indicative of future amounts and additional awards in future years are
anticipated.
I. EMPLOYEE'S SAVING PLAN:
The Company provides a 401(k) Plan to employees of the Company by which
they may defer compensation for income tax purposes under Section 401(k) of the
Internal Revenue Code. Each employee may elect to defer a percentage of his or
her salary on a pre-tax basis up to a specified maximum percentage. The Company
matches every dollar each employee contributes to the 401(k) Plan up to six
percent of each employee's salary to a maximum of $2,000 annually per employee.
Salary deferred by employees and contributions by the Company to the 401(k) Plan
are not taxable to employees until withdrawn from the 401(k) Plan and
contributions are deductible by the Company when made. The amount of the
Company's matching contribution for the 401(k) Plan was $95,753, $99,710, and
$104,943 for fiscal 1999, 1998, and 1997, respectively.
J. COMMON STOCK TRANSACTIONS:
In November 1997, the Board of Directors extended the authorization granted
in May 1996 to purchase 250,000 shares of the Company's common stock in the
aggregate on the open market. Through September 30, 1999, the Company purchased
122,200 shares for $1,574,244 and the shares have been retired.
K. PREFERRED STOCK:
The preferred stock may be issued from time to time in one or more series.
The rights, preferences, restrictions, qualifications and limitations of such
stock shall be determined by the Board of Directors.
L. BUSINESS CUSTOMERS:
The Company's operations are located solely within the United States. The
Company is focused principally on developing and manufacturing contrast agents.
The Company performs ongoing credit evaluations of its customers and generally
does not require collateral. Two customers accounted for 70.1% and 25.3%
respectively, of the Company's product revenues in fiscal 1999. The same two
customers accounted for 56% and 19% respectively, of the Company's product
revenues in fiscal 1998. One customer accounted for 54% of the Company's product
revenues in fiscal 1997.
Revenues in fiscal 1999 from customers and licensees outside of the United
States, principally in Europe, amounted to 19% of the Company's total revenues.
Product revenues in fiscal 1998 from customers and licensees outside of the
United States, again principally in Europe, amounted to 26% of the Company's
total revenues. Product revenues from customers and licensees outside the United
States were not significant in fiscal 1997.
39
<PAGE> 41
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
M. BUSINESS SEGMENTS:
During fiscal 1999, the Company adopted FASB Statement No. 131 ("SFAS
131"), "Disclosures about Segments of an Enterprise and Related Information."
This Statement changes the way public companies report information about
segments. Prior to the deconsolidation of Kalisto, the Company had two business
segments under the "management approach" as defined in SFAS 131, the original
business and the majority-owned subsidiary. Information concerning the
operations in these reportable segments is as follows:
<TABLE>
<CAPTION>
FOR THE YEARS ENDED SEPTEMBER 30,
-----------------------------------------
1999 1998 1997
----------- ----------- -----------
<S> <C> <C> <C>
Revenues:
Advanced Magnetics, Inc............................. $ 6,511,654 $ 5,823,454 $11,001,771
Kalisto Biologicals Inc............................. 918,402 227,098 --
----------- ----------- -----------
Total............................................. $ 7,430,056 $ 6,404,146 $11,001,771
Depreciation Expense:
Advanced Magnetics, Inc............................. $ 764,861 $ 968,683 $ 1,112,539
Kalisto Biologicals Inc............................. 52,438 30,939 --
----------- ----------- -----------
Total............................................. $ 817,299 $ 999,622 $ 1,112,539
Income Tax (Expense) Benefit:
Advanced Magnetics, Inc............................. $ -- $ -- $ (379,022)
Kalisto Biologicals Inc............................. -- -- --
----------- ----------- -----------
Total............................................. $ -- $ -- $ (379,022)
Net Income (Loss):
Advanced Magnetics, Inc............................. $(3,476,742) $(5,120,713) $ 583,174
Kalisto Biologicals Inc............................. (965,676) (1,382,806) --
Eliminations and adjustments........................ -- 194,178 --
----------- ----------- -----------
Total............................................. $(4,442,418) $(6,309,341) $ 583,174
Eliminations and adjustments for 1998 represent minority interest in share of net loss.
Segment Assets:
Advanced Magnetics, Inc............................. $27,816,359 $35,230,857 $44,976,181
Kalisto Biologicals Inc............................. -- 688,512 --
Eliminations and adjustments........................ -- (1,804,661) --
----------- ----------- -----------
Total............................................. $27,816,359 $34,114,708 $44,976,181
Eliminations and adjustments for 1998 represent intercompany receivables eliminated in
consolidation.
</TABLE>
N. LEGAL PROCEEDINGS:
The Company and certain of its officers were sued in an action entitled
David D. Stark, M.D. v. Advanced Magnetics, Inc., Jerome Goldstein, Ernest V.
Groman, and Lee Josephson, Civil Action No. 92-12157-WGY, in the United States
District Court for the District of Massachusetts on September 3, 1992. The
plaintiff, a former consultant to the Company, claims that he was incorrectly
omitted as an inventor or joint inventor on certain of the Company's patents and
on pending applications, and seeks injunctive relief and unspecified damages. In
addition, the complaint also alleges state law claims for breach of contract,
breach of good faith and fair dealing, breach of implied contract,
misappropriation of trade secrets, conversion, negligent misrepresentation,
misrepresentation, unjust enrichment and unfair trade practices. The District
Court has stayed this federal action pending resolution of an appeal in the
State Court of summary judgment in the Company's favor as well as resolution of
jurisdictional issue. While the outcome of the action cannot be
40
<PAGE> 42
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
determined, the Company believes the action is without merit and intends to
defend the action vigorously. The Company may not be able to successfully defend
this action and the failure by the Company to prevail for any reason could have
an adverse effect on its future business, financial condition and results of
operations.
The Company and certain of its officers were sued in David D. Stark, M.D.
v. Advanced Magnetics, Inc., Jerome Goldstein, Ernest V. Groman and Lee
Josephson, Civil Action No. 93-02846-C, in the Superior Court Department of the
Massachusetts Trial Court for Middlesex County. This case involves claims of
breach of contract, breach of good faith and fair dealing, breach of implied
contract, unjust enrichment and unfair trade practices that were originally
dismissed by, but later remanded to, the Federal Court in the above-mentioned
action, as well as a new count alleging tortious interference with contractual
or advantageous relations. The Superior Court granted partial summary judgment
in the Company's favor and dismissed the unfair trade practices and tort counts.
The plaintiff's contract claims have been dismissed with prejudice and final
judgment was entered against the plaintiff. The plaintiff filed an appeal in
David D. Stark, M.D. v. Advanced Magnetics, Inc., Jerome Goldstein, Ernest V.
Groman and Lee Josephson, Appeal No. 98-P-1749 in the Massachusetts Appeals
Court, on January 25, 1999. While the outcome of the action cannot be
determined, the Company believes the action is without merit and intends to
defend the action vigorously. The Company may not be able to successfully defend
this action and the failure by the Company to prevail for any reason could have
an adverse effect on its future business, financial condition and results of
operations.
The Company filed suit on October 7, 1997 against Sanofi Pharmaceuticals,
Inc. (formerly known as Sanofi Winthrop, Inc.) and Sanofi SA (collectively,
"Defendants") in the Superior Court of the Commonwealth of Massachusetts. The
action is entitled Advanced Magnetics, Inc. v. Sanofi Pharmaceuticals, Inc. and
Sanofi SA, Civil Action No. 97-5222B. The Company claims that the Defendants
tortiously interfered with a license, supply and marketing agreement (the
"Agreement"), and seeks unspecified monetary damages. In addition, the Company
seeks a declaration that the Defendants do not have any rights under the
Agreement and that the Company has not breached the Agreement. Sanofi
Pharmaceuticals, Inc., filed counterclaims against the Company on February 4,
1998 seeking compensatory damages of $11,500,000 and multiple damages as a
result of the Company's alleged breach of the Agreement. Sanofi Pharmaceuticals,
Inc. also filed a motion to dismiss the Company's tortious interference claim,
which the Court denied on July 3, 1998. On October 26, 1998, the Company served
a motion for partial summary judgment which, among other things, requests
judgment in its favor on all of Sanofi Pharmaceuticals, Inc.'s counterclaims. On
November 13, 1998, the Company filed an amended complaint adding claims for
unfair competition and breach of contract against the Defendants. On November
23, 1998, Defendants answered the Company's amended complaint, and Sanofi
Pharmaceuticals, Inc. served a new set of counterclaims seeking compensatory
damages of $15,000,000 and multiple damages as a result of the Company's alleged
conduct. On December 18, 1998, the Court held a hearing on the Company's motion
for partial summary judgment. On June 15, 1999, the Court granted partial
summary judgment in favor of the Company and against the Defendants, declared
that the Company did not breach the Agreement, was not unjustly enriched, and
did not violate Mass. Gen. Laws ch. 93A, and dismissed Sanofi Pharmaceuticals,
Inc.'s counterclaims for breach of contract, unjust enrichment, conversion
account annexed and violation of Mass. Gen. Laws ch. 93A. On October 29, 1999,
the Company served a motion for partial summary judgment which, among other
things, requests judgment in its favor on Sanofi Pharmaceuticals, Inc.'s
remaining counterclaims against the Company and for judgment in its favor on the
Company's breach of contract claim against Sanofi Pharmaceuticals, Inc. Also on
October 29, 1999, Sanofi Pharmaceuticals, Inc. served a motion for partial
summary judgment which, among other things, requests judgment in its favor on
the Company's remaining claims. While the final outcome of the remaining claims
and counterclaims cannot be determined, the Company will pursue its claims
vigorously, and believes that Sanofi Pharmaceuticals, Inc.'s remaining
counterclaims are equally without merit and intends to defend them vigorously.
The Company may not be able to successfully defend the counterclaims and the
failure by the Company to prevail for any reason could have an adverse effect on
its future business, financial condition or results of operations.
41
<PAGE> 43
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
O. AGREEMENTS:
To facilitate the marketing and distribution of its contrast agents, the
Company has entered into strategic relationships with certain established
pharmaceutical companies. These companies, both in the United States and abroad,
include: (i) Guerbet S.A. ("Guerbet"), a leading European producer of contrast
agents, in western Europe and Brazil; (ii) Eiken Chemical Co., Ltd. ("Eiken"),
one of Japan's leading medical diagnostics manufacturers, in Japan; (iii) Berlex
Laboratories, Inc. ("Berlex"), the leading U.S. marketer of MRI contrast agents,
in the United States; and (iv) Mallinckrodt Inc. ("Mallinckrodt") a leading
manufacturer of contrast agents, in the United States, Canada and Mexico.
On February 1, 1995, the Company entered into an agreement with Berlex
granting Berlex a product license and exclusive marketing rights to Feridex I.V.
in the United States and Canada. Under the terms of the agreement, Berlex paid a
$5,000,000 non-refundable license fee in fiscal 1995. An additional $5,000,000
license fee was received in October 1996 as a result of the FDA's marketing
approval and Berlex' market launch of Feridex I.V. in the United States. In
addition, the Company receives payments for manufacturing the product and
royalties on sales. Under the terms of the license and marketing agreement,
Berlex pays for 60% of ongoing development expenses associated with Feridex I.V.
These agreements expire in 2010 but can be terminated earlier upon the
occurrence of certain specified events. Under the terms of the agreement, the
Company has the right to terminate the exclusivity of the marketing rights based
on inadequate sales performance by Berlex, but has not exercised that right at
this time.
In 1991, the Company entered into agreements with Squibb Diagnostics, a
division of Bristol-Myers Squibb Co. ("Squibb Diagnostics") covering certain
technology and the manufacturing and marketing of certain contrast agents
including Combidex, which agreements have been terminated. Under agreements
returning the products and technology rights to Advanced Magnetics, the Company
is obligated to pay Squibb Diagnostics up to a maximum of $2,750,000 in
royalties in connection with product sales of Combidex.
In 1990, the Company entered into a manufacturing and distribution
agreement with Mallinckrodt granting Mallinckrodt a product license and
co-marketing rights to GastroMARK in the United States, Canada and Mexico. Under
the terms of the agreement, Mallinckrodt paid a $500,000 non-refundable license
fee in fiscal 1997 as a result of the FDA's marketing approval of Feridex I.V.
in the United States. In addition, the company received payments for
manufacturing the product and royalties on sales.
The Company is the licensee of certain technologies under agreements with
third parties which require the Company to make payments in accordance with
these license agreements and upon the attainment of particular milestones. The
Company is also required to pay royalties on a percentage of certain product
sales, if any. During fiscal year 1997 the Company made milestone payments of
$800,000 in relation to these agreements. There were no milestone payments in
fiscal years 1998 or 1999. Future milestone payments are not to exceed $400,000.
P. RELATED PARTY TRANSACTIONS:
During the fiscal years ended September 30, 1999, 1998 and 1997, the
Company paid approximately $33,329, $58,410 and $58,910, respectively, to
Fahnestock & Co. Inc. as commissions on transactions involving its investments
in securities. Mr. Leslie Goldstein, a shareholder and former member of the
Company's Board of Directors and the brother of Jerome Goldstein, Chairman of
the Board and CEO of the Company, is employed by SRG Associates, a division of
Fahnestock & Co. Inc., as an investment analyst and advisor.
42
<PAGE> 44
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
Q. CONSOLIDATED QUARTERLY FINANCIAL DATA -- UNAUDITED:
The following table provides quarterly data for the fiscal years ended
September 30, 1999, and 1998.
<TABLE>
<CAPTION>
FISCAL 1999 QUARTERS ENDED
-----------------------------------------------------------
SEPTEMBER 30 JUNE 30 MARCH 31 DEC. 31, 1998
------------ ----------- ----------- -------------
<S> <C> <C> <C> <C>
License fees.......................... $ -- $ -- $ -- $ --
Royalties............................. 220,000 100,000 200,000 160,000
Product sales......................... 383,866 264,113 1,001,239 316,841
Research and development services..... 106,241 85,430 144,856 244,902
Interest, dividends and net gains and
losses on sales of securities....... 2,671,172 400,982 937,638 192,776
----------- ----------- ----------- -----------
Total revenues.............. 3,381,279 850,525 2,283,733 914,519
Cost of product sales................. 90,954 95,604 155,903 112,181
Cost of contract research............. 17,138 4,103 15,815 --
Operating expenses.................... 1,817,524 3,088,904 3,327,433 3,412,508
Other (income) expense................ 155,968 -- (421,561) --
----------- ----------- ----------- -----------
Net income (loss)..................... $ 1,299,695 $(2,338,086) $ (793,857) $(2,610,170)
=========== =========== =========== ===========
Basic and diluted net income (loss)
per share........................... $ 0.19 $ (0.35) $ (0.12) $ (0.39)
</TABLE>
<TABLE>
<CAPTION>
FISCAL 1998 QUARTERS ENDED
-----------------------------------------------------------
SEPTEMBER 30 JUNE 30 MARCH 31 DEC. 31, 1997
------------ ----------- ----------- -------------
<S> <C> <C> <C> <C>
License fees.......................... $ -- $ -- $ -- $ --
Royalties............................. 180,542 60,000 370,000 370,000
Product sales......................... 605,689 170,158 619,464 4,560
Research and development services..... 399,897 -- -- --
Interest, dividends and net gains and
losses on sales of securities....... 371,511 1,263,335 996,977 992,013
----------- ----------- ----------- -----------
Total revenues.............. 1,557,639 1,493,493 1,986,441 1,366,573
Cost of product sales................. 99,679 28,947 103,514 5,805
Operating expenses.................... 3,478,718 2,967,515 3,108,987 3,114,500
Minority shareholder interest......... -- (40,637) (80,243) (73,298)
----------- ----------- ----------- -----------
Net income (loss)..................... $(2,020,758) $(1,462,332) $(1,145,817) $(1,680,434)
=========== =========== =========== ===========
Basic and diluted net income (loss)
per share........................... $ (0.30) $ (0.22) $ (0.17) $ (0.25)
</TABLE>
R. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS:
In June 1998, the FASB issued Statement No. 133 ("SFAS 133"), "Accounting
for Derivative Instruments and Hedging Activities" which is effective for fiscal
years beginning after June 15, 2000. The statement establishes accounting and
reporting standards requiring that every derivative instrument be recorded in
the balance sheet as either an asset or liability, measured at its fair value.
SFAS No. 133 also requires that changes in the derivative's fair value be
recognized currently in earnings unless specific hedge accounting criteria are
met. Adoption of this standard is not expected to have a material impact on the
financial position or results of operations of the Company.
43
<PAGE> 45
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE:
Not applicable.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT:
The information required by this item, with respect to the directors of the
registrant, is incorporated by reference from the Company's definitive proxy
statement in connection with its Annual Meeting of Stockholders to be held on
February 1, 2000, filed with the Commission on or about December 22, 1999, under
the caption "Election of Directors."
The information required by this item, with respect to executive officers
of the registrant, can be found in Part I hereof.
ITEM 11. EXECUTIVE COMPENSATION:
The information required by this item is incorporated by reference from the
Company's definitive proxy statement in connection with its Annual Meeting of
Stockholders to be held on February 1, 2000, filed with the Commission on or
about December 22, 1999, under the captions "Compensation of Directors" and
"Compensation and Other Information Concerning Directors and Officers."
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT:
The information required by this item is incorporated by reference from the
Company's definitive proxy statement in connection with its Annual Meeting of
Stockholders to be held on February 1, 2000, filed with the Commission on or
about December 22, 1999, in the table under the caption "Principal
Stockholders."
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS:
Not applicable.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K:
(a) The following documents are filed as part of this Annual Report on Form
10-K:
1. Financial Statement Schedules. Financial statement schedules have
been omitted because the required information is not present or not present
in amounts sufficient to require submission of the schedule, or because the
information required is included in the financial statements or the notes
thereto.
2. The exhibits listed in the Exhibit Index immediately preceding the
Exhibits are filed as a part of this Annual Report on Form 10-K.
(b) Reports on Form 8-K:
No reports on Form 8-K were filed by the Company during the fiscal
quarter ended September 30, 1999.
44
<PAGE> 46
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
ADVANCED MAGNETICS, INC.
By: /s/ JEROME GOLDSTEIN
----------------------------------
Jerome Goldstein, Chairman of the
Board of Directors, Chief Executive
Officer and Treasurer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
NAME TITLE DATED
---- ----- -----
/s/ JEROME GOLDSTEIN Chairman of the Board of December 17, 1999
- ----------------------------- Directors, Chief Executive
Jerome Goldstein Officer and Treasurer
(principal executive and
financial officer)
/s/ JAMES MATHESON Vice President -- Finance December 17, 1999
- ----------------------------- (principal accounting
James Matheson officer)
/s/ LEONARD M. BAUM Director December 17, 1999
- -----------------------------
Leonard M. Baum
/s/ JOSEPH B. LASSITER, III Director December 17, 1999
- -----------------------------
Joseph B. Lassiter, III, Ph.D
/s/ MICHAEL D. LOBERG Director December 17, 1999
- -----------------------------
Michael D. Loberg, Ph.D
/s/ EDWARD B. ROBERTS Director December 17, 1999
- -----------------------------
Edward B. Roberts, Ph.D.
/s/ GEORGE M. WHITESIDES Director December 17, 1999
- -----------------------------
George M. Whitesides, Ph.D
45
<PAGE> 47
EXHIBIT INDEX
<TABLE>
<CAPTION>
SEQUENTIALLY
EXHIBIT NUMBERED
NUMBER DESCRIPTION PAGE
- ------- ----------- ------------
<C> <S> <C>
3.1(1) Certificate of Incorporation of the Company, as amended.
3.2(2) By-Laws of the Company, as amended.
10.1(3) 1983 Stock Option Plan of the Company, as amended on
November 13, 1990.
10.2(4) 1992 Non-Employee Director Stock Option Plan.
10.3(5) 1993 Stock Plan, as amended on February 2, 1999.
10.4(5) 1993 Non-Employee Director Stock Option Plan.
10.5(6) 1997 Employee Stock Purchase Plan.
10.6(2) Clinical Testing, Supply and Marketing Agreement between the
Company and Guerbet S.A. dated May 22, 1987 (confidential
treatment previously granted).
10.7(7) Clinical Testing, Supply and Marketing Agreement between the
Company and Eiken Chemical Co., Ltd. dated August 30, 1988
(confidential treatment previously granted).
10.8(8) Contrast Agent Agreement between the Company and Guerbet
S.A. dated September 29, 1989 (confidential treatment
previously granted).
10.9(3) Contrast Agent Agreement between the Company and Eiken
Chemical Co., Ltd. dated March 27, 1990 (confidential
treatment previously granted).
10.10(3) Amendment to Clinical Testing, Supply and Marketing
Agreement between the Company and Eiken Chemical Co., Ltd.
dated September 29, 1990 (confidential treatment previously
granted).
10.11(3) License, Supply and Marketing Agreement between the Company
and Mallinckrodt Medical, Inc. dated June 28, 1990
(confidential treatment previously granted).
10.12(4) Technology License Agreement between the Company and Squibb
Diagnostics, dated February 5, 1991 (confidential treatment
previously granted).
10.13(4) Agreement of Amendment to Clinical Testing, Supply and
Marketing Agreement between the Company and Guerbet, S.A.,
dated August 13, 1990.
10.14(9) Termination Agreement dated August 30, 1994 between the
Company and Bristol-Myers Squibb Co.
10.15(10) License and Marketing Agreement between the Company and
Berlex Laboratories, Inc. dated as of February 1, 1995.
10.16(10) Supply Agreement between the Company and Berlex
Laboratories, Inc. dated as of February 1, 1995.
10.17(11) Lease and Lease Agreement between the Company and Carnegie
Center Associates dated September 6, 1994.
10.18(12) Promissory Note dated February 10, 1998 issued to the
Company by Leonard Baum.
23.1 Consent of PricewaterhouseCoopers LLP, independent
accountants.
27 Financial Data Schedule.
</TABLE>
- ---------------
(1) Incorporated herein by reference to the exhibits to the Company's
Registration Statement on Form S-8 (File No. 33-13953).
(2) Incorporated herein by reference to the exhibits to the Company's Annual
Report on Form 10-K for the fiscal year ended September 30, 1987.
(3) Incorporated herein by reference to the exhibits to the Company's Annual
Report on Form 10-K for the fiscal year ended September 30, 1990.
(4) Incorporated herein by reference to the exhibits to the Company's Annual
Report on Form 10-K for the fiscal year ended September 30, 1991.
46
<PAGE> 48
(5) Incorporated herein by reference to the exhibits to the Company's
definitive proxy statement for the fiscal year ended September 30, 1992.
(6) Incorporated herein by reference to the exhibits to the Company's
definitive proxy statement for the fiscal year ended September 30, 1996.
(7) Incorporated herein by reference to the exhibits to the Company's Annual
Report on Form 10-K for the fiscal year ended September 30, 1988.
(8) Incorporated herein by reference to the exhibits to the Company's Annual
Report on Form 10-K for the fiscal year ended September 30, 1989.
(9) Incorporated herein by reference to the exhibits to the Company's Annual
Report on Form 10-K, for the fiscal year ended September 30, 1994.
(10) Incorporated herein by reference to the exhibits to the Company's Quarterly
Report on Form 10-Q, for the fiscal quarter ended December 31, 1994.
(11) Incorporated herein by reference to the exhibits to the Company's Annual
Report on Form 10-K, for the fiscal year ended September 30, 1997.
(12) Incorporated herein by reference to the exhibits to the Company's Quarterly
Report on Form 10-Q, for the fiscal quarter ended March 31, 1998.
47
<PAGE> 1
EXHIBIT 23.1
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the incorporation by reference in the Registration Statements
of Advanced Magnetics, Inc. on Forms S-8 (File Nos. 33-8697, 33-13953, 33-40744,
33-46963, and 333-28417) of our report, dated November 9, 1999, on our audits of
the financial statements of Advanced Magnetics, Inc. as of September 30, 1999
and 1998, and for the years ended September 30, 1999, 1998, and 1997, which
report is included in this Annual Report on Form 10-K.
/s/ PRICEWATERHOUSECOOPERS LLP
Boston, Massachusetts
December 17, 1999
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> SEP-30-1999
<PERIOD-START> OCT-01-1998
<PERIOD-END> SEP-30-1999
<CASH> 17,052,636
<SECURITIES> 4,804,785
<RECEIVABLES> 814,778
<ALLOWANCES> 166,577
<INVENTORY> 80,480
<CURRENT-ASSETS> 22,781,757
<PP&E> 13,738,460
<DEPRECIATION> 9,065,660
<TOTAL-ASSETS> 27,816,359
<CURRENT-LIABILITIES> 761,650
<BONDS> 0
0
0
<COMMON> 67,521
<OTHER-SE> 44,205,370
<TOTAL-LIABILITY-AND-EQUITY> 27,816,359
<SALES> 1,966,059
<TOTAL-REVENUES> 7,430,056
<CGS> 454,642
<TOTAL-COSTS> 12,138,067
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (4,442,418)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (4,442,418)
<EPS-BASIC> (0.66)
<EPS-DILUTED> (0.66)
</TABLE>
